



National
Comprehensive
Cancer
Network®

NCCN Clinical Practice Guidelines in Oncology™

Thyroid Carcinoma

V.1.2009

Continue

www.nccn.org

NCCN Thyroid Carcinoma Panel Members

* Steven I. Sherman, MD/Chair ð
The University of Texas
M. D. Anderson Cancer Center

* R. Michael Tuttle, MD/Co-Chair ð
Memorial Sloan-Kettering
Cancer Center

Douglas W. Ball, MD ð
The Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins

David Byrd, MD ¶
Fred Hutchinson Cancer Research
Center/Seattle Cancer Care Alliance

Orlo H. Clark, MD ¶
UCSF Helen Diller Family Comprehensive
Cancer Center

Gilbert H. Daniels, MD ð
Massachusetts General Hospital
Cancer Center

Raza A. Dilawari, MD ¶
St. Jude Children's Research Hospital/
University of Tennessee Cancer Institute

Gerard M. Doherty, MD ¶
University of Michigan
Comprehensive Cancer Center

Hormoz Ehya, MD ≠
Fox Chase Cancer Center

William B. Farrar, MD ¶
Arthur G. James Cancer Hospital and
Richard J. Solove Research Institute at
The Ohio State University

Robert I. Haddad, MD †
Dana-Farber/Brigham and Women's
Cancer Center

Fouad Kandeel, MD, PhD ð
City of Hope

* Richard T. Kloos, MD ð φ
Arthur G. James Cancer Hospital &
Richard J. Solove Research Institute at
The Ohio State University

Peter Kopp, MD ð
Robert H. Lurie Comprehensive Cancer
Center of Northwestern University

Dominick M. Lamonica, MD ⊃ φ
Roswell Park Cancer Institute

Thom R. Loree, MD ¶
Roswell Park Cancer Institute

William M. Lydiatt, MD ¶
UNMC Eppley Cancer Center at The
Nebraska Medical Center

Judith McCaffrey, MD ζ
H. Lee Moffitt Cancer Center
& Research Institute

John A. Olson, Jr., MD, PhD ¶
Duke Comprehensive Cancer Center

Lee Parks, MD ð
Vanderbilt-Ingram Cancer Center

John A. Ridge, MD, PhD ¶
Fox Chase Cancer Center

Jatin P. Shah, MD ¶
Memorial Sloan-Kettering
Cancer Center

Cord Sturgeon, MD ¶
Robert H. Lurie Comprehensive Cancer
Center of Northwestern University

* Steven G. Waguespack, MD ð
The University of Texas
M. D. Anderson Cancer Center

Thomas N. Wang, MD
University of Alabama at Birmingham
Comprehensive Cancer Center

Lori J. Wirth, MD †
Massachusetts General Hospital
Cancer Center

ð Endocrinology
¶ Surgery/Surgical oncology
† Medical Oncology
≠ Pathology
⊃ Internal medicine
φ Nuclear Medicine
ζ Otolaryngology
* Writing Committee Member

Continue

[NCCN Guidelines Panel Disclosures](#)

Table of Contents

[NCCN Thyroid Carcinoma Panel Members](#)

[Summary of Guidelines Updates](#)

[Nodule Evaluation \(THYR-1\)](#)

[Principles of TSH Suppression \(THYR-A\)](#)

Papillary Carcinoma

• [FNA positive \(PAP-1\)](#)

• [Incidental finding postlobectomy \(PAP-2\)](#)

[Follicular Carcinoma \(FOLL-1\)](#)

[Hürthle Cell Carcinoma \(HÜRT-1\)](#)

Medullary Carcinoma

• [Diagnosed by FNA \(MEDU-1\)](#)

• [Germline mutation of RET proto-oncogene \(MEDU-2\)](#)

[Anaplastic Carcinoma \(ANAP-1\)](#)

[Guidelines Index](#)

[Print the Thyroid Carcinoma Guideline](#)

[For help using these documents, please click here](#)

[Staging](#)

[Discussion](#)

[References](#)

This manuscript is being updated to correspond with the newly updated algorithm.

Clinical Trials: The NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN member institutions, [click here: nccn.org/clinical_trials/physician.html](#)

NCCN Categories of Evidence and Consensus: All recommendations are Category 2A unless otherwise specified.

See [NCCN Categories of Evidence and Consensus](#)

These guidelines are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network makes no representations nor warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. These guidelines are copyrighted by National Comprehensive Cancer Network. All rights reserved. These guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2009.

Summary of the Guidelines updates

Summary of changes in the 1.2009 version of the Thyroid Carcinoma Guidelines from the 1.2008 version include:

Thyroid Nodule Evaluation

THYR-1

- Clinical Presentation; Second bullet: “Age < 15 or > 45 y” changed to “Age < 15 y”.

THYR-2

- The procedures for evaluating thyroid nodules have been revised---especially those for follicular or Hürthle cell neoplasms or for follicular lesions of undetermined significance---which cannot be diagnosed by fine needle aspiration (FNA). The diagnostic categories for FNA results have been revised and reflect recent data from the National Cancer Institute state of the science conference, which have been carefully evaluated by the NCCN panel.

THYR-A Principles of Thyroid Stimulating Hormone (TSH) Suppression

- Principles of TSH Suppression is a new page that provides specific recommendations for levothyroxine use for TSH suppression throughout the Papillary, Follicular, and Hürthle Cell Guidelines.

Papillary Carcinoma

PAP-1

- FNA Finding: Footnote “a” was added stating, “There is a potential role for frozen section if FNA is suspicious but not diagnostic for papillary carcinoma”.
- Diagnostic Procedures:
 - ▶ Third bullet: “Consider lateral neck ultrasound” changed from category 2B to category 2A. (Also for FOLL-1 and HÜRT-1)
 - ▶ “CT/MRI for fixed or substernal...” changed to “CT/MRI for fixed, bulky, or substernal...” (Also for FOLL-1 and HÜRT-1)
- Last column: “Suppress TSH with thyroxine” changed to “Consider levothyroxine therapy to keep TSH low or normal”. (Also for PAP-2, FOLL-1, and HÜRT-1)
- “Thyroxine” changed to “Levothyroxine” throughout the algorithm. (Also for the Follicular Carcinoma and Hürthle Cell Carcinoma algorithms)

PAP-2

- Second column: “Chest x-ray, if not recently done” changed to “Consider chest x-ray...”
- Third column: “Macroscopic multifocal disease” was removed from the middle pathway and placed in the top pathway. “Confirmed nodal metastasis” was added to the top pathway.
- Last column: “Thyroxine therapy to keep TSH low/normal” changed to “Suppress TSH with levothyroxine”.

PAP-3

- “No gross residual disease in neck” pathway: After the “TSH + thyroglobulin measurement...” recommendation, the decision points for “≥ 1 cm” and “< 1 cm” changed to a new “Consider radioiodine (RAI) therapy” pathway. (Also for FOLL-2 and HÜRT-2)

PAP-4

- Second column: “...or Clinical indication for radioiodine therapy (category 2B)” was added (Also for FOLL-3 and HÜRT-3).
- Postsurgical therapy: “Adjuvant radioiodine ablation (30-100 mCi) of thyroid bed” changed from category 2B to category 2A. (Also for FOLL-3 and HÜRT-3)

PAP-5

- Surveillance and Maintenance: (Also for FOLL-4 and HÜRT-4)
 - ▶ Third bullet: Changed to “TSH stimulated thyroglobulin in patients previously treated with RAI and with negative TSH-suppressed thyroglobulin and anti-thyroglobulin antibodies”.
 - ▶ New bullet added that states, “Consider TSH-stimulated radioiodine scan in patients T3-4 or M1 at initial staging, or with abnormal thyroglobulin levels (either TSH-suppressed or TSH-stimulated), abnormal antithyroglobulin antibodies, or abnormal ultrasound during surveillance”.
 - ▶ Last bullet regarding ¹³¹I scan was revised for clarity.
- Footnote “i” was added stating, “In selected patients who may be at higher risk for residual/recurrent disease (eg, N1 patients), obtain a stimulated thyroglobulin and consider a concomitant diagnostic RAI scan. With a positive stimulated Tg, the concomitant RAI scan may help determine whether treatment with RAI is indicated (i.e. RAI is often beneficial in iodine-avid disease but not in non-iodine avid disease).” (Also for FOLL-4 and HÜRT-4)

Summary of the Guidelines updates

Papillary Carcinoma ---continued

PAP-6

- CNS; Treatment: Image-guided RT: Footnote stating that this recommendation does not include whole brain RT was removed from the page. (Also for FOLL-5 and HÜRT-5)
- “Any extracervical sites” changed to “Sites other than CNS”.
- Other than CNS; Treatment: “Consider surgical resection of selected...” changed to “Consider surgical resection and/or RT of selected...” (Also for FOLL-5 and HÜRT-5)
- “...clinical trials for non-radioiodine avid tumors; sorafenib...” changed to “clinical trials for non-radioiodine avid tumors; consider small molecule kinase inhibitors”, with corresponding new footnote “n” that states, “While not FDA approved for treatment of thyroid cancer, commercially available small molecule kinase inhibitors (such as sorafenib or sunitinib) can be considered if clinical trials are not available or appropriate.” (Also for FOLL-5 and HÜRT-5)

Follicular Carcinoma (Also see the Papillary Carcinoma Updates)

FOLL-1

- Pathology Finding: Changed to “Follicular neoplasm or Follicular lesion of undetermined significance”.
- Diagnostic Procedures: “Chest x-ray” changed to “Consider chest x-ray. (Also for HÜRT-1)
- After Primary Treatment, two new branch points were added: “Benign” and “Follicular carcinoma”.

Hürthle Cell Carcinoma (Also see the Papillary Carcinoma Updates)

HÜRT-1

- Pathology Finding: Changed to “Hürthle cell neoplasm or Lesion of undetermined significance”.
- After Primary Treatment, two new branch points were added: “Benign” and “Hürthle cell carcinoma”.

Medullary Carcinoma

MEDU-1

- Primary Treatment: “Consider ipsilateral modified radical neck dissection...” changed to “...modified neck dissection...”

- Primary Treatment; Third bullet: Changed to “Consider adjuvant RT for T4 disease involving major neck structures”. (Also for MEDU-3)

- Footnote about when to evaluate for exon 8 was deleted.

MEDU-2

- MEN 2A pathway: The recommendation “Calcium stimulated calcitonin test if calcitonin undetectable (category 2B for use in timing of surgery)” was removed.
- Footnote “b”: The second sentence was revised and now states, “Prophylactic thyroidectomy may be delayed in patients with these less high risk, later onset RET mutations, provided the annual calcitonin measurement is normal, the annual ultrasound (US) is unremarkable, there is no history of aggressive MTC in the family, and the family is in agreement.” (Also for MEDU-3)

MEDU-3

- After “No primary hyperparathyroidism”, the recommendation, “Evaluate for other causes of hypercalcemia” was removed.
- Primary hyperparathyroidism, Primary Treatment; Fourth bullet: The recommendation regarding multiglandular disease was reworded for clarity.

MEDU-4

- New footnote “f” stating, “Bone scan, FDG-PET scan, and MRI of axial skeleton should be considered in patients with very elevated calcitonin levels” was added.

MEDU-5

- Last column: “Sorafenib” changed to “Small molecule kinase inhibitors” with corresponding footnote “g” stating, “While not FDA approved for treatment of thyroid cancer, commercially available small molecule kinase inhibitors (such as sorafenib or sunitinib) can be considered if clinical trials are not available or appropriate.”

Anaplastic Carcinoma

ANAP-1

- Diagnostic Procedures: The following recommendations were added “Consider FDG-PET scan” and “Consider bone scan”.
- Footnote “a” regarding FNA diagnosis and core biopsy was revised.

CLINICAL PRESENTATION

- Solitary nodule > 1 cm in diameter^a
- Increased suspicion if any of the following are present:^b
 - ▶ Age < 15 y
 - ▶ Male sex
 - ▶ Nodule > 4 cm in diameter
 - ▶ History of radiation exposure
 - ▶ History of diseases associated with thyroid cancer:
 - ◊ Pheochromocytoma
 - ◊ MEN2
 - ◊ Gardner’s syndrome
 - ◊ Familial adenomatous polyposis
 - ◊ Carney complex
 - ◊ Cowden’s syndrome
 - ▶ Suspicious criteria by ultrasound
 - ◊ Central hypervascularity
 - ◊ Irregular border
 - ◊ Microcalcification
 - ▶ Incidentally identified focal PET positive lesion in the thyroid
- Highly suspicious:^c
 - ▶ Rapid nodule growth
 - ▶ Very firm nodule
 - ▶ Fixation to adjacent structures
 - ▶ Family history of thyroid cancer
 - ▶ Vocal cord paralysis
 - ▶ Enlarged regional lymph nodes
 - ▶ Symptoms of invasion into neck structures

WORKUP

- Clinically euthyroid:
- TSH measurement
 - Ultrasound of thyroid and neck including central and lateral neck compartments (category 2B)
 - FNA of nodule
 - FNA of clinically suspicious lymph nodes

[See FNA Results \(THYR-2\)](#)

Nodules < 1 cm in diameter without suspicious findings and without suspicious lymph nodes by ultrasound, or simple cyst

- Follow-up as clinically indicated
- Consider lateral neck ultrasound
- If findings consistent with criteria of increased suspicion - see above pathway

[See Primary Treatment \(THYR-2\)](#)

Thyroid nodule with unknown TSH

Thyroid nodule with low TSH


Papillary carcinoma, finding postlobectomy for benign disease

[See Primary Treatment \(PAP-2\)](#)



^aIn selected cases, it may be reasonable to follow with serial ultrasounds.
^bPatients with elevated TSH levels, may have an increased risk of malignancy.
^cConsider surgery after FNA.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.


FNA RESULTS



Diagnostic categories for FNA results reflect NCI state of the science conference, available from <http://www.cytojournal.com/content/5/1/6>. Cytology reports should be interpreted in light of terminology used by local cytopathologists.



Thyroid lymphoma → [See NCCN Non-Hodgkin's Lymphoma Guideline](#)



Benign^f →

- Observe
- If nodule growth, repeat FNA or consider surgery

^d Alternative term: Suspicious for follicular or Hürthle cell neoplasm . Estimated risk of malignancy is 20%-30%.

^e Alternative terms include: Atypia of undetermined significance, rule out neoplasm, atypical follicular lesion, and cellular follicular lesion. Estimated risk of malignancy is 5%-10%.

^f Includes nodular goiter, colloid nodule, hyperplastic/adenomatoid nodule, Hashimoto's thyroiditis. Estimated risk of malignancy is < 1%.

^g Surgery usually means a diagnostic lobectomy for these follicular lesions.

Note: All recommendations are category 2A unless otherwise indicated.


Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

PRINCIPLES OF THYROID STIMULATING HORMONE (TSH) SUPPRESSION

Because TSH is a trophic hormone that can stimulate the growth of cells derived from thyroid follicular epithelium, the use of levothyroxine to maintain low TSH levels is considered optimal in treatment of patients with papillary, follicular, or Hürthle cell carcinoma. However, data are lacking to permit precise specification of the appropriate serum levels of TSH. In general, patients with known residual carcinoma or at high risk for recurrence should have TSH levels maintained below 0.1 mU/L, whereas disease-free patients at low risk for recurrence should have TSH levels maintained either slightly below or slightly above the lower limit of the reference range. Patients who remain disease free for several years can probably have their TSH levels maintained within the reference range. Given the potential toxicities associated with TSH-suppressive doses of levothyroxine---including cardiac tachyarrhythmias and bone demineralization as well as frank symptoms of thyrotoxicosis---the risk and benefit of TSH-suppressive therapy must be balanced for each individual patient. Patients whose TSH levels are chronically suppressed should be counseled to ensure adequate daily intake of calcium (1200 mg/day) and vitamin D (800 units/day).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



^aThere is a potential role for frozen section if FNA is suspicious but not diagnostic for papillary carcinoma.

^bAge is an approximation and not an absolute determination.

^cTall cell, columnar cell, insular, oxyphilic, or poorly differentiated features.

^dPossible benefit to reduce recurrence must be balanced with risk of hypoparathyroidism.

^e[See Principles of TSH Suppression \(THYR-A\).](#)


Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

[See Surveillance and Maintenance \(PAP-5\)](#)

CLINICAL PRESENTATION

PRIMARY TREATMENT




^cTall cell, columnar cell, insular, oxyphilic, or poorly differentiated features.

^eSee Principles of TSH Suppression (THYR-A).

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

POSTSURGICAL EVALUATION
AFTER THYROIDECTOMY




^eSee Principles of TSH Suppression (THYR-A).

^fSuspicion based on pathology, postoperative thyroglobulin, and intraoperative findings.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

POSTSURGICAL THERAPY



^eSee Principles of TSH Suppression (THYR-A).

^fSuspicion based on pathology, postoperative thyroglobulin, and intraoperative findings.

^gAll patients should be examined, and palpable neck disease should be surgically resected before radioiodine treatment.


Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

SURVEILLANCE AND MAINTENANCE

- Physical examination, TSH and thyroglobulin measurement + antithyroglobulin antibodies at 6 and 12 mo, then annually if disease-free
- Periodic neck ultrasound^h
- TSH stimulated thyroglobulin in patients previously treated with RAI and with negative TSH-suppressed thyroglobulin and anti-thyroglobulin antibodiesⁱ
- Consider TSH-stimulated radioiodine scan in patients with T3-4 or M1 at initial staging, or with abnormal thyroglobulin levels (either TSH-suppressed or TSH-stimulated), abnormal antithyroglobulin antibodies, or abnormal ultrasound during surveillance
- If detectable thyroglobulin or distant metastases or soft tissue invasion on initial staging, radioiodine scan every 12 mo until no response is seen to RAI treatment in iodine avid tumors (either withdrawal of thyroid hormone or rhTSH)^j
- If ¹³¹I scans negative and stimulated Tg > 2-5 ng/mL, consider additional nonradioiodine imaging (eg, FDG PET ± CT if Tg ≥ 10 ng/mL)

RECURRENT DISEASE



^eSee Principles of TSH Suppression (THYR-A).


^hA subgroup of low risk patients may only require an ultrasound if there is a reasonable suspicion for recurrence.

ⁱIn selected patients who may be at higher risk for residual/recurrent disease (eg, N1 patients), obtain a stimulated thyroglobulin and consider a concomitant diagnostic RAI scan. With a positive stimulated Tg, the concomitant RAI scan may help determine whether treatment with RAI is indicated (ie, RAI is often beneficial in iodine-avid disease but not in non-iodine avid disease).

^jIf there is a high likelihood of therapy, thyroid hormone withdrawal suggested; if not, suggest using rhTSH.

^kConsider preoperative vocal cord assessment, if central neck recurrence.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



^eSee Principles of TSH Suppression (THYR-A).

^lFor solitary lesions, either neurosurgical resection or stereotactic radiosurgery preferred.

^mCytotoxic chemotherapy has shown to have minimal efficacy. Clinical trials investigating novel targeted therapies are ongoing.

[See Clinical trials available at the NCCN member institutions.](#)

ⁿWhile not FDA approved for treatment of thyroid cancer, commercially available small molecule kinase inhibitors (such as sorafenib or sunitinib) can be considered if clinical trials are not available or appropriate.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

PATHOLOGY FINDING

DIAGNOSTIC PROCEDURES

PRIMARY TREATMENT

Follicular neoplasm or Follicular lesion of undetermined significance (See [THYR-2](#))

- Consider chest x-ray
- Consider lateral neck ultrasound
- CT/MRI for fixed bulky or substernal lesions (avoid iodinated contrast, unless essential)
- Evaluate vocal cord mobility (category 2B)

Total thyroidectomy if invasive cancer, metastatic cancer, or patient decision
If lymph node(s) positive:

- Central neck dissection (level VI)
- Lateral neck dissection (levels II-IV, consider for level V, sparing spinal accessory nerve, internal jugular vein, and sternocleidomastoid muscle)

Consider preservation of the cervical sensory nerves

or

Lobectomy/isthmusectomy

Benign

Follicular carcinoma

Invasive cancer (extensive vascular invasion)

Minimally invasive cancer^a

Follicular adenoma

Completion of thyroidectomy

Consider completion of thyroidectomy

or
Observe

Observe

Levothyroxine therapy to keep TSH normal^b

See [Postsurgical Evaluation \(FOLL-2\)](#)

Consider levothyroxine therapy to keep TSH low or normal^b


See [Surveillance and Maintenance \(FOLL-4\)](#)

^aMinimally invasive cancer is characterized as a well-defined tumor with microscopic capsular and/or a few foci of vascular invasion and often requires examination of at least 10 histologic sections to demonstrate.

^bSee [Principles of TSH Suppression \(THYR-A\)](#).

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

POSTSURGICAL EVALUATION
AFTER THYROIDECTOMY




^bSee Principles of TSH Suppression (THYR-A).

^cSuspicion based on pathology, postoperative thyroglobulin, and intraoperative findings.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

POSTSURGICAL THERAPY



^bSee Principles of TSH Suppression (THYR-A).

^cSuspicion based on pathology, postoperative thyroglobulin, and intraoperative findings.

^dAll patients should be examined, and palpable neck disease should be surgically resected before radioiodine treatment.


Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

SURVEILLANCE AND MAINTENANCE

- Physical examination, TSH and thyroglobulin measurement + antithyroglobulin antibodies at 6 and 12 mo, then annually if disease-free
- Periodic neck ultrasound^e
- TSH stimulated thyroglobulin in patients previously treated with RAI and with negative TSH-suppressed thyroglobulin and anti-thyroglobulin antibodies^f
- Consider TSH-stimulated radioiodine scan in patients with T3-4 or M1 at initial staging, or with abnormal thyroglobulin levels (either TSH-suppressed or TSH-stimulated), abnormal antithyroglobulin antibodies, or abnormal ultrasound during surveillance.
- If detectable thyroglobulin or distant metastases or soft tissue invasion on initial staging, radioiodine scan every 12 mo until no response is seen to RAI treatment in iodine avid tumors (either withdrawal of thyroid hormone or rhTSH)^g
- If ¹³¹I scans negative and stimulated Tg > 2-5 ng/mL, consider additional nonradioiodine imaging (eg, FDG PET ± CT if Tg ≥ 10 ng/mL)

RECURRENT DISEASE



^b[See Principles of TSH Suppression \(THYR-A\).](#)

^eA subgroup of low risk patients may only require an ultrasound if there is a reasonable suspicion for recurrence.


^fIn selected patients who may be at higher risk for residual/recurrent disease (eg, N1 patients), obtain a stimulated thyroglobulin and consider a concomitant diagnostic RAI scan. With a positive stimulated Tg, the concomitant RAI scan may help determine whether treatment with RAI is indicated (ie, RAI is often beneficial in iodine-avid disease but not in non-iodine avid disease).

^gIf there is a high likelihood of therapy, thyroid hormone withdrawal suggested; if not, suggest using rhTSH.

^hConsider preoperative vocal cord assessment, if central neck recurrence.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



^bSee Principles of TSH Suppression (THYR-A).

ⁱFor solitary lesions, either neurosurgical resection or stereotactic radiosurgery preferred.

^jCytotoxic chemotherapy has shown to have minimal efficacy. Clinical trials investigating novel targeted therapies are ongoing.

See Clinical trials available at the NCCN member institutions.

^kWhile not FDA approved for treatment of thyroid cancer, commercially available small molecule kinase inhibitors (such as sorafenib or sunitinib) can be considered if clinical trials are not available or appropriate.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

PATHOLOGY FINDING

DIAGNOSTIC PROCEDURES

PRIMARY TREATMENT

Hürthle cell neoplasm or Lesion of undetermined significance (See [THYR-2](#))

- Consider chest x-ray
- Consider lateral neck ultrasound
- CT/MRI for fixed, bulky, or substernal lesions (avoid iodinated contrast unless essential)
- Evaluate vocal cord mobility (category 2B)

Total thyroidectomy, if invasive cancer or patient decision
If lymph node(s) positive:
• Central neck dissection (level VI)
• Lateral neck dissection (Level II-IV, consider for level V, sparing spinal accessory nerve, internal jugular vein, and sternocleidomastoid muscle)
Consider preservation of the cervical sensory nerves
If node(s) negative, consider prophylactic central neck dissection (category 2B)^a

or

Lobectomy/isthmusectomy

Benign

Hürthle cell carcinoma

Invasive cancer (extensive vascular invasion)

Minimally invasive cancer^b

Hürthle adenoma

Completion of thyroidectomy

Strongly consider completion of thyroidectomy

or
Observe

Observe

Levothyroxine therapy to keep TSH normal^c

See [Postsurgical Evaluation \(HÜRT-2\)](#)

Consider levothyroxine therapy to keep TSH low or normal^c

See [Surveillance and Maintenance \(HÜRT-4\)](#)

^aPossible benefit to reduce recurrence must be balanced with risk of hypoparathyroidism.


^bMinimally invasive cancer is characterized as a well-defined tumor with microscopic capsular and/or a few foci of vascular invasion and often requires examination of at least 10 histologic sections to demonstrate.

^cSee [Principles of TSH Suppression \(THYR-A\)](#).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

POSTSURGICAL EVALUATION
AFTER THYROIDECTOMY




^cSee Principles of TSH Suppression (THYR-A).

^dSuspicion based on pathology, postoperative thyroglobulin, and intraoperative findings.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

POSTSURGICAL THERAPY



^cSee Principles of TSH Suppression (THYR-A).

^dSuspicion based on pathology, postoperative thyroglobulin, and intraoperative findings.

^eAll patients should be examined and palpable neck disease should be surgically resected before radioiodine treatment.


Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

SURVEILLANCE AND MAINTENANCE

- Physical examination, TSH and thyroglobulin measurement + antithyroglobulin antibodies at 6 and 12 mo, then annually if disease-free
- Periodic neck ultrasound^f
- TSH stimulated thyroglobulin in patients previously treated with RAI and with negative TSH-suppressed thyroglobulin and anti-thyroglobulin antibodies^g
- Consider TSH-stimulated radioiodine scan in patients with T3-4 or M1 at initial staging, or with abnormal thyroglobulin levels (either TSH-suppressed or TSH-stimulated), abnormal antithyroglobulin antibodies, or abnormal ultrasound during surveillance.
- If detectable thyroglobulin or distant metastases or soft tissue invasion on initial staging, radioiodine scan every 12 mo until no response is seen to RAI treatment in iodine avid tumors (either withdrawal of thyroid hormone or rhTSH)^h
- If ¹³¹I scans negative and stimulated Tg > 2-5 ng/mL, consider additional nonradioiodine imaging (eg, FDG PET ± CT if Tg ≥ 10 ng/mL)

RECURRENT DISEASE



^cSee Principles of TSH Suppression (THYR-A).

^fA subgroup of low risk patients may only require an ultrasound if there is a reasonable suspicion for recurrence.


^gIn selected patients who may be at higher risk for residual/recurrent disease (eg, N1 patients), obtain a stimulated thyroglobulin and consider a concomitant diagnostic RAI scan. With a positive stimulated Tg, the concomitant RAI scan may help determine whether treatment with RAI is indicated (ie, RAI is often beneficial in iodine-avid disease but not in non-iodine avid disease).

^hIf there is a high likelihood of therapy, thyroid hormone withdrawal suggested; if not, suggest using rhTSH.

ⁱConsider preoperative vocal cord assessment, if central neck recurrence.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



^cSee Principles of TSH Suppression (THYR-A).

^jFor solitary lesions, either neurosurgical resection or stereotactic radiosurgery preferred.

^kCytotoxic chemotherapy has shown to have minimal efficacy. Clinical trials investigating novel targeted therapies are ongoing.

[See Clinical trials available at the NCCN member institutions.](#)

^lWhile not FDA approved for treatment of thyroid cancer, commercially available small molecule kinase inhibitors (such as sorafenib or sunitinib) can be considered if clinical trials are not available or appropriate.


Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

CLINICAL
PRESENTATION

ADDITIONAL WORKUP

PRIMARY TREATMENT



^aGermline mutation should prompt family testing of first-degree relatives and genetic counseling. ([See NCCN Neuroendocrine Tumors Guidelines](#))


Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

CLINICAL
PRESENTATION

ADDITIONAL WORKUP

PRIMARY TREATMENT



^bLethality of medullary thyroid carcinoma associated with codon 768, 790, 791, and 804 RET mutations may be lower than with other RET mutations. Prophylactic thyroidectomy may be delayed in patients with these less high risk, later onset RET mutations, provided the annual calcitonin measurement is normal, the annual ultrasound is unremarkable, there is no history of aggressive MTC in the family, and the family is in agreement. Brandi ML, Gagel RF, Angeli A, et al. Consensus: Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86(12):5658-5671.


^cEvidence of pheochromocytoma should be evaluated and treated appropriately before proceeding to the next step on the pathway.

^dScreening for pheochromocytoma (MEN 2A and 2B) and hyperparathyroidism (MEN 2A) should be performed annually. For some RET mutations (codons 768, 790, V804M, or 891) less frequent screening may be appropriate.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

CLINICAL
PRESENTATION




^bLethality of medullary thyroid carcinoma associated with codon 768, 790, 791, and 804 RET mutations may be lower than with other RET mutations. Prophylactic thyroidectomy may be delayed in patients with these less high risk, later onset RET mutations, provided the annual calcitonin measurement is normal, the annual US is unremarkable, there is no history of aggressive MTC in the family, and the family is in agreement. Brandi ML, Gagel RF, Angeli A, et al. Consensus: Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86(12):5658-5671.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

MANAGEMENT
2-3 MONTHS
POSTOPERATIVE

SURVEILLANCE




^eThe likelihood of significant residual disease with a negative basal calcitonin is very low.

^fBone scan, FDG-PET scan, and MRI of axial skeleton should be considered in patients with very elevated calcitonin levels.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

RECURRENT OR PERSISTENT DISEASE




⁹While not FDA approved for treatment of thyroid cancer, commercially available small molecule kinase inhibitors (such as sorafenib or sunitinib) can be considered if clinical trials are not available or appropriate.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

FNA OR CORE
BIOPSY FINDING

DIAGNOSTIC
PROCEDURES

PRIMARY TREATMENT



^aAn FNA diagnosis suspicious for anaplastic carcinoma should consider core biopsy.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

Staging (2002 AJCC 6th Edition)

Table 1

American Joint Committee on Cancer (AJCC)
TNM Staging For Thyroid Cancer

Primary Tumor (T)

Note: All categories may be subdivided: (A) solitary tumor, (b) multifocal tumor (the largest determines the classification).

- TX** Primary tumor cannot be assessed
- T0** No evidence of primary tumor
- T1** Tumor 2 cm or less in greatest dimension limited to the thyroid
- T2** Tumor more than 2 cm but not more than 4 cm in greatest dimension limited to the thyroid
- T3** Tumor more than 4 cm in greatest dimension limited to the thyroid or any tumor with minimal extrathyroid extension (eg, extension to sternothyroid muscle or perithyroid soft tissues)
- T4a** Tumor of any size extending beyond the thyroid capsule to invade subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve
- T4b** Tumor invades prevertebral fascia or encases carotid artery or mediastinal vessels

All anaplastic carcinomas are considered T4 tumors.

- T4a** Intrathyroidal anaplastic carcinoma – surgically resectable
- T4b** Extrathyroidal anaplastic carcinoma – surgically unresectable

Regional Lymph Nodes (N)

Regional lymph nodes are the central compartment, lateral cervical, and upper mediastinal lymph nodes.

- NX** Regional lymph nodes cannot be assessed
- N0** No regional lymph node metastasis
- N1** Regional lymph node metastasis
- N1a** Metastasis to Level VI (pretracheal, paratracheal, and prelaryngeal/Delphian lymph nodes)
- N1b** Metastasis to unilateral, bilateral, or contralateral cervical or superior mediastinal lymph nodes

Distant Metastasis (M)

- MX** Distant metastasis cannot be assessed
- M0** No distant metastasis
- M1** Distant metastasis

Stage grouping:

Separate stage groupings are recommended for papillary or follicular, medullary, and anaplastic (undifferentiated) carcinoma.

Papillary or Follicular
Under 45 Years

- Stage I** Any T Any N M0
- Stage II** Any T Any N M1

Papillary or Follicular
45 Years and Older

- Stage I** T1 N0 M0
- Stage II** T2 N0 M0
- Stage III** T3 N0 M0
- T1 N1a M0
- T2 N1a M0
- T3 N1a M0
- Stage IVA** T4a N0 M0
- T4a N1a M0
- T1 N1b M0
- T2 N1b M0
- T3 N1b M0
- T4a N1b M0
- Stage IVB** T4b Any N M0
- Stage IVC** Any T Any N M1

Medullary Carcinoma

- Stage I** T1 N0 M0
- Stage II** T2 N0 M0
- Stage III** T3 N0 M0
- T1 N1a M0
- T2 N1a M0
- T3 N1a M0
- Stage IVA** T4a N0 M0
- T4a N1a M0
- T1 N1b M0

- T2 N1b M0
- T3 N1b M0
- T4a N1b M0
- Stage IVB** T4b Any N M0
- Stage IVC** Any T Any N M1

Anaplastic Carcinoma

All anaplastic carcinomas are considered Stage IV

- Stage IVA** T4a Any N M0
- Stage IVB** T4b Any N M0
- Stage IVC** Any T Any N M1

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Sixth Edition (2002) published by Springer-Verlag New York. (For more information, visit www.cancerstaging.net.) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer-Verlag New York, Inc., on behalf of the AJCC.

Histopathologic Type

There are four major histopathologic types:

- Papillary carcinoma (including follicular variant of papillary carcinoma)
- Follicular carcinoma (including Hurthle cell carcinoma)
- Medullary carcinoma
- Undifferentiated (anaplastic) carcinoma

Discussion

This discussion is being updated to correspond with the newly updated algorithm. Last updated 09/03/08

NCCN Categories of Evidence and Consensus

Category 1: The recommendation is based on high-level evidence (e.g. randomized controlled trials) and there is uniform NCCN consensus.

Category 2A: The recommendation is based on lower-level evidence and there is uniform NCCN consensus.

Category 2B: The recommendation is based on lower-level evidence and there is nonuniform NCCN consensus (but no major disagreement).

Category 3: The recommendation is based on any level of evidence but reflects major disagreement.

All recommendations are category 2A unless otherwise noted.

Overview

Epidemiology

Thyroid nodules are approximately 4 times more common in women than in men. These nodules increase in frequency throughout life, reaching a prevalence of about 5% in the U.S. population aged 50 years and older.¹ Nodules are even more prevalent when the thyroid gland is examined at autopsy or surgery, or when using ultrasonography; 50% of the thyroids so studied have nodules, which are almost always benign.^{1,2} New nodules develop at a rate of about 0.1% per year, beginning in early life, but they develop at a much higher rate (about 2% per year) after exposure to head and neck irradiation.^{3,4}

By contrast, thyroid carcinoma is uncommon. For the U.S. population, the lifetime risk of being diagnosed with thyroid carcinoma is less than

1% (0.84% for women and 0.30% for men).⁵ Approximately 37,340 new cases of thyroid carcinoma will be diagnosed in the United States in the year 2008.⁶ As with thyroid nodules, this cancer occurs 2 to 3 times more often in women than in men. With the incidence increasing by 6.2% per year, thyroid cancer is currently the eighth most common malignancy diagnosed in women. Among persons aged 15 to 24 years, thyroid cancer accounts for 7.5% to 10% of all diagnosed malignancies.⁷ The disease is also diagnosed more often in white North Americans than in African Americans. Although thyroid carcinoma can occur at any age, the peak incidence is around age 45 to 49 years in women and 65 to 69 years in men for the period 2000 to 2004.⁵

There are 3 main histologic types of thyroid cancer: differentiated (including papillary, follicular, and Hürthle), medullary, and anaplastic. Information from the National Cancer Data Base (NCDB) indicates that of 53,856 patients treated for thyroid carcinoma between 1985 and 1995, 80% had papillary carcinoma, 11% had follicular carcinoma, 3% had Hürthle cell carcinoma, 4% had medullary carcinoma, and 2% had anaplastic thyroid carcinoma.⁸ In 2008, approximately 1590 cancer deaths will occur among persons living with thyroid carcinoma in the United States.⁶ Thyroid carcinoma occurs more often in women; however, mortality rates are higher for men, probably because men are usually older at the time of diagnosis.^{5,9}

The incidence of thyroid carcinoma increased almost 310% between 1950 and 2004, but mortality rates decreased more than 44%.⁵ From 1975 to 2004, thyroid cancer rates in the United States doubled. Because overall mortality has remained stable since 1975, the increasing incidence probably partially reflects earlier detection of subclinical disease (ie, small papillary cancers), although even microcarcinomas can metastasize regionally, thereby increasing eventual recurrence risk.^{10,11} It is also notable that the stable age- and gender-adjusted mortality rate for thyroid carcinoma contrasts distinctly

with the declining rates being observed with other solid tumors in adults.⁶

The Challenge of Managing Differentiated Thyroid Carcinoma

Managing differentiated (ie, papillary, follicular, and Hürthle) thyroid carcinoma can be a challenge, because no prospective randomized trials of treatment have been done. Results from ongoing randomized trials will not be available for many years, given the typically prolonged course and relative infrequency of these tumors. Most of the information about treatment comes from studies of large patient cohorts in which therapy has not been randomly assigned. This accounts for much of the disagreement about managing differentiated carcinoma. Nonetheless, most patients can be cured of this disease when properly treated by experienced physicians and surgeons.¹² The treatment of choice is surgery, whenever possible, followed in many patients by radioiodine (¹³¹I) and thyroxine therapy. External-beam radiation therapy (RT) and chemotherapy have less prominent roles in managing these tumors.

Radiation-Induced Thyroid Carcinoma

Exposure to ionizing radiation is the only known environmental cause of thyroid carcinoma, usually causing papillary carcinoma. The thyroid glands of children are especially vulnerable to the carcinogenic action of ionizing radiation. A child's thyroid gland has one of the highest risks of developing cancer of any organ. In fact, the thyroid gland is the only organ linked to risk at about 0.10 Gy by convincing evidence.³ The risk of radiation-induced thyroid carcinoma is greater in females, certain Jewish populations, and patients with a family history of thyroid carcinoma.¹³ This suggests that genetic factors are also important in its development. Beginning within 5 years of irradiation, new nodules develop at a rate of about 2% annually, reaching a peak incidence within 30 years of irradiation but remaining high at 40 years.^{3,4}

Previously, most studies showed that ¹³¹I is less effective than external gamma radiation in inducing thyroid carcinoma.¹⁴ However, most of the studies that came to this conclusion involved adults, in whom the risk of developing thyroid carcinoma after exposure to ¹³¹I appears to be small or nonexistent.¹⁵ After the Chernobyl nuclear reactor accident in 1986, many children developed papillary thyroid carcinoma after being exposed to radioiodine fallout. It became evident that ¹³¹I and other short-lived radioiodines were potent thyroid carcinogens in children, particularly those who were younger than 10 years when they were exposed.¹⁶ Although radiation-induced papillary thyroid cancer tends to appear more aggressive histologically and to have high recurrence rates, the prognosis for survival is not clearly different from that of spontaneously occurring tumors.^{17,18}

Differentiated Thyroid Carcinoma

Clinical Presentation and Diagnosis

Differentiated (ie, papillary, follicular, or Hürthle) thyroid carcinoma is usually asymptomatic for long periods and commonly presents as a solitary thyroid nodule. However, evaluating all nodules for malignancy is difficult, because benign nodules are so prevalent and thyroid carcinoma, by contrast, is so uncommon.¹ Moreover, both benign and malignant thyroid nodules are usually asymptomatic, giving no clinical clue to their diagnosis. About 50% of the malignant nodules are discovered during a routine physical examination, by serendipity on imaging studies, or during surgery for benign disease. The other 50% are usually first noticed by the patient, usually as an asymptomatic nodule.¹ Regrettably, the typically indolent nature of differentiated thyroid carcinoma often leads to long delays in diagnosis that may substantially worsen the course of the disease.⁹

Factors Affecting Risk of Malignancy

Nodule size has a bearing on the risk of malignancy and the clinical evaluation. Thyroid nodules smaller than 1 cm occur with such

frequency in the asymptomatic general population that they are found, in many cases, by serendipity when performing imaging studies for other head or neck problems. Often termed “incidentalomas,” nodules smaller than 1 cm are almost invariably clinically benign lesions and usually do not require biopsy.^{1,2,19} In selected cases, it may be reasonable to follow these nodules with serial ultrasounds. By contrast, nodules more than 4 cm in diameter are more suggestive and pose a somewhat higher risk of malignancy. Fine-needle aspiration (FNA) is the procedure of choice for evaluating suspicious thyroid nodules.²⁰ The Society of Radiologists in Ultrasound wrote a consensus statement about management of thyroid nodules identified at thyroid ultrasonography. Their recommendations describe which nodules should undergo FNA and which should not based on nodule size and ultrasound characteristics, and on clinical features that might predict risk of morbidity from an undiagnosed malignancy.²¹ Suspicious criteria by ultrasound include central hypervascularity, microcalcifications, and irregular borders.

Although more than 50% of all malignant nodules are asymptomatic, the pretest probability of malignancy in a nodule increases considerably when signs or symptoms are present.²² For example, the likelihood that a nodule is malignant increases about 7-fold if it is very firm, fixed to adjacent structures, associated with enlarged regional lymph nodes, causes vocal cord paralysis, or is rapidly growing or if symptoms of invasion into neck structures are present.^{22,23} If 2 or more of these features are present, the likelihood of thyroid cancer is virtually assured.²³

A patient's age and gender also affect the probability of malignancy. The risk of malignancy is higher in patients younger than 15 years and older than 60 years. In particular, a man older than 60 years with a thyroid nodule has about 4 times the risk of having thyroid carcinoma than does a middle-aged woman with a thyroid nodule.²⁴ Other factors

that increase the suspicion of malignancy include (1) a history of head and neck irradiation; (2) a family history of thyroid carcinoma; (3) the presence of familial syndromes associated with thyroid carcinoma (see “Familial Syndromes”), such as Gardner's syndrome, familial adenomatous polyposis, Carney complex, Cowden's syndrome, and multiple endocrine neoplasia (MEN) types 2A or 2B; (4) evidence of other diseases seen with thyroid cancer--associated diseases or syndromes such as hyperparathyroidism, pheochromocytoma, marfanoid habitus, and mucosal neuromas (MEN2B), which make the presence of medullary thyroid cancer, more likely; or (5) the presence of suspicious findings detected by imaging such as focal FDG (18-fluorodeoxyglucose) uptake on positron emission tomography (PET), or central hypervascularity, irregular border, and/or microcalcifications on ultrasound.²⁵

Initial Workup

Fine-needle aspiration of the nodule and clinically suspicious lymph nodes is recommended as the first diagnostic test in a clinically euthyroid patient before any imaging studies are done.¹ Ideally, the serum thyrotropin (thyroid-stimulating hormone [TSH]) results should be known before FNA is performed. This is often impractical, however, and FNA may be done during the initial office visit.

Some clinicians, especially in Europe,²⁶ recommend obtaining serum calcitonin levels from all patients with thyroid nodules. However, there is controversy surrounding the cost effectiveness of this practice in the United States, especially in the absence of confirmatory pentagastrin stimulation testing, and the assumptions used in cost effective analyses. To date, this practice has not been recommended by the American Thyroid Association.²⁷ A recent study showed that calcitonin screening may be cost effective in the United States.²⁸ However, false-positive calcitonin readings that can result from minimal calcitonin elevations can only be ruled out with pentagastrin testing, and

pentagastrin is not available in the United States. Ultrasound of the thyroid and neck including central and lateral neck compartments is also recommended (category 2B).²⁹

Cytologic examination of an FNA specimen, with sufficient cells recovered to assign a diagnosis, is typically categorized as (1) carcinoma; (2) suspicious for malignancy, including follicular neoplasms; (3) thyroid lymphoma; and (4) benign (such as macrofollicular, colloid adenoma, Hashimoto's thyroiditis, Hürthle cells in the absence of neoplasm). Both the National Cancer Institute (NCI) (<http://thyroidfna.cancer.gov/pages/conclusions/>) and the Papanicolaou Society of Cytopathology have guidelines for thyroid FNA (<http://www.papsociety.org/guidelines.html>).

Pathology and cytopathology slides should be reviewed at the treating institution by a pathologist with expertise in the diagnosis of thyroid disorders. Although FNA is a very sensitive test—particularly for papillary—false-negative results are sometimes obtained; therefore, a reassuring FNA should not override concerns in the presence of worrisome clinical findings.³⁰

Pathology synoptic reports (protocols) are useful for reporting results from examinations of surgical specimens; these reports assist pathologists in providing clinically useful and relevant information. The National Comprehensive Cancer Network (NCCN) thyroid panel is in favor of pathology synoptic reports from the (1) College of American Pathologists (CAP), and (2) the Association of Directors of Anatomic and Surgical Pathology (ADASP). Some pathologists currently use a modified format that is felt to comply with both of these synoptic reports. Although there is no published ADASP checklist for thyroid carcinoma, the CAP protocol information and checklists can be accessed at:

http://www.cap.org/apps/cap.portal?nfpb=true&cntvwrPtlit_actionOverride=%2Fportlets%2FcontentViewer%2Fshow&_windowLabel=cntvwrPtlit

http://www.cancer.gov/committees/fca/ncr%2Fprotocols%2Fprotocols_index.html&state=maximized&_pageLabel=cntvwr

On January 1, 2004, the Commission on Cancer (COC) of the American College of Surgeons mandated the use of specific checklist elements of the protocols as part of its Cancer Program Standards for Approved Cancer Programs. Therefore, pathologists should familiarize themselves with these documents. The CAP protocol checklist complies with the COC requirements.

FNA is far less able to discriminate follicular and Hürthle cell carcinomas from benign adenomas, because the diagnostic criterion for these malignancies requires demonstration of vascular or capsular invasion. Thus, follicular and Hürthle cell carcinomas are rarely diagnosed on FNA. Nodules that yield an abundance of follicular cells with little or no colloid are nearly impossible to categorize as benign or malignant on the basis of FNA. Surgical biopsy is advisable, because approximately 20% of these lesions are follicular carcinomas.²² Male gender, older patient age, and larger nodule size may increase the likelihood of a malignant diagnosis at surgery as high as 80%, whereas female gender, younger age, and smaller nodule size may reduce the risk as low as 5%. Repeat FNA will not resolve the diagnostic dilemma. Before thyroidectomy is performed, however, serum TSH level and thyroid ¹²³I or 99m technetium scanning may identify patients with an autonomously functioning or “hot” nodule who often may be spared surgery, because the diagnosis of follicular adenoma is highly likely.³¹ Clinically euthyroid patients with a low TSH and a hot nodule on thyroid scan should be evaluated and treated for thyrotoxicosis as indicated even when cytology is suspicious for follicular neoplasm; those with a “cold” nodule should proceed to surgery. Those patients with a high or normal TSH and cytology suspicious for follicular or Hürthle cell neoplasm should undergo open biopsy with thyroidectomy. A trial of

thyroxine therapy may be considered for a small, clinically nonsuspicious, follicular neoplasm in a young female patient, although the panel disagreed about this recommendation (category 3). If the patient receives thyroxine therapy, re-aspiration or surgery should be performed if the lesion grows.

Nodules yielding benign cytology do not require repeat FNA unless the nodules show evidence of growth.²² The use of thyroid hormone to suppress benign thyroid nodules is controversial with modest clinical impact at best, and a perceived cost/benefit ratio that is not compelling.^{32,33}

An FNA that yields insufficient cellular material for diagnosis should be repeated, because approximately 50% of subsequent specimens are adequate to assign a diagnosis.²² In patients with serial nondiagnostic aspirates, 5% of women and 30% of men may prove to have malignant nodules.³⁴

When a diagnosis of thyroid carcinoma is promptly established using FNA, the tumor is often confined to the thyroid or has metastasized only to regional nodes, thus providing ample opportunity for cure. However, as many as 5% of patients with papillary carcinoma and up to 10% of those patients with follicular or Hürthle cell carcinoma have tumors that aggressively invade structures in the neck or have produced distant metastases. Such cancers are difficult to cure.

Prognosis and Recurrence of Differentiated Thyroid Carcinoma

In the NCDB study, the 10-year relative survival rates for patients with papillary, follicular, and Hürthle cell carcinomas were 93%, 85%, and 76%, respectively.⁸ Although anaplastic thyroid carcinoma is almost uniformly lethal, most thyroid carcinoma deaths are from papillary, follicular, and Hürthle cell carcinomas, which account for nearly 95% of all thyroid carcinoma cases.

Depending on initial therapy and other prognostic variables, about 30% of patients with differentiated thyroid carcinoma have tumor recurrences during several decades; 66% of these recurrences occur within the first decade after initial therapy.⁹ Although not usually fatal, a recurrence in the neck is serious and must be regarded as the first sign of a potentially lethal outcome.^{35,36} In one large study, central neck recurrences were seen most often in the cervical lymph nodes (74%), followed by the thyroid remnant (20%), and then the trachea or muscle (6%). Of the group with local recurrences, 8% eventually died of cancer.⁹ Distant metastases were the sites of recurrence in 21% of this patient cohort, most often (63%) in the lungs alone. Of the patients with distant metastases, 50% died of cancer.⁹

Age, Stage, and Sex at Diagnosis

Although many factors influence the outcome for patients with papillary and follicular thyroid carcinomas, the 2 most important and consistently demonstrable are patient age at the time of initial therapy and tumor stage.^{9,37-39} Age is the most important prognostic variable for thyroid cancer mortality. However, thyroid cancer is more aggressive in men. Thyroid carcinoma is more lethal in patients older than 40 years, increasingly so with each subsequent decade of life. The mortality rate increases dramatically after age 60 years (see [Figure 1](#)). However, tumor recurrence shows a remarkably different behavior with respect to age. Recurrence frequencies are highest (40%) for those younger than 20 years or older than 60 years; recurrence at other ages ensues in only about 20% of patients.^{9,37-40} This disparity between cancer-related mortality and the frequency of tumor recurrence probably accounts for most of the profound disparity of opinion among clinicians concerning optimal treatment for patients with differentiated thyroid cancer. How clinicians assess the importance of tumor recurrence (as opposed to cancer-specific survival) accounts for much of the debate surrounding the influence of age on the treatment plan for children and young adults.

Children typically present with more advanced disease and have more tumor recurrences after therapy than adults, yet their prognosis for survival is good.^{41,42} One study found, however, that although the prognosis of children with thyroid carcinoma is favorable for long-term survival (90% at 20 years), the standardized mortality ratio was 8-fold higher than predicted.⁴³ Some authors believe that young age in a patient imparts such a favorable influence on survival that it overshadows the behavior expected from the characteristics of the tumor. Therefore, they classify most thyroid tumors as low-risk tumors that may be treated with lobectomy alone,⁴⁴⁻⁴⁶ although most physicians treating the disease believe that tumor stage and its histologic features should be as significant as the patient's age in determining management.^{9,41,47,48}

Prognosis is less favorable in men than in women, but the difference is usually small.^{9,46} One study found that gender was an independent prognostic variable for survival and that the risk of death from cancer was about twice as high in men as in women.⁹ Because of this risk factor, men with thyroid carcinoma, especially those who are older than 40 years, may be regarded with special concern.⁴⁹

Familial Syndromes

Familial, nonmedullary thyroid carcinoma accounts for about 5% of papillary carcinomas and, in some cases, may be clinically more aggressive than the sporadic form.⁵⁰ One study found that microscopic familial papillary thyroid carcinoma tends to be multifocal and bilateral, often with vascular invasion, lymph node metastases, and high rates of recurrence and distant metastases.⁵¹ Other familial syndromes associated with papillary thyroid carcinoma are Gardner's syndrome, familial adenomatous polyposis,⁵² Carney complex (multiple neoplasia and lentiginosis syndrome which affects endocrine glands),⁵³ and Cowden's syndrome (multiple hamartomas).⁵⁴ The prognosis for all of

these syndromes is not different from the prognosis of spontaneously occurring papillary thyroid carcinoma.

Tumor Variables Affecting Prognosis

Some tumor features have a profound influence on prognosis.^{40,55-57} Perhaps the most important features are tumor histology, primary tumor size, local invasion, necrosis, vascular invasion, BRAF mutation status, and metastases. A somatic RET oncogene mutation in sporadic medullary thyroid cancer confers an adverse prognosis.⁵⁸

Histology

Although survival rates with typical papillary carcinoma are quite good, cancer-specific mortality rates vary considerably with certain histologic subsets of tumors.¹ A well-defined tumor capsule, which is found in about 10% of papillary thyroid carcinomas, is a particularly favorable prognostic indicator. A worse prognosis is associated with (1) anaplastic tumor transformation; (2) tall-cell papillary variants, which have a 10-year mortality of up to 25%; (3) columnar variant papillary carcinoma (a rapidly growing tumor with a high mortality rate); and (4) diffuse sclerosing variants, which infiltrate the entire gland.⁵⁹ Follicular-variant papillary carcinoma, which is recognized by its follicular architecture and typical papillary cytology, does not appear to have a worse prognosis than the pure papillary lesions.^{40,59,60}

Follicular carcinoma is typically a solitary encapsulated tumor that may be more aggressive than papillary carcinoma. It usually has a microfollicular histologic pattern. It is identified as cancer by follicular cell invasion of the tumor capsule and/or blood vessels. The latter has a worse prognosis than capsular penetration alone.⁶¹ Many follicular carcinomas are minimally invasive tumors, exhibiting only slight tumor capsular penetration without vascular invasion. They closely resemble follicular adenomas and are less likely to produce distant metastases or to cause death.⁶² FNA or frozen section study cannot differentiate a

minimally invasive follicular carcinoma from a follicular adenoma. Therefore, the tumor is often simply referred to as a “follicular neoplasm” by the cytopathologist. The diagnosis of cancer may be assigned only after thyroidectomy and indeed only after analysis of the “permanent” histologic sections shows tumor capsule invasion by follicular cells.

Highly invasive follicular carcinomas are much less common; they are sometimes recognized at surgery by their invasion of surrounding tissues and extensive invasion of blood vessels. Up to 80% of these cancers metastasize, causing death in as many as 20% of patients, often within a few years of diagnosis.⁴⁰ The poor prognosis is closely related to the patient’s older age at the time of diagnosis, advanced tumor stage, and larger tumor size.⁹

The mortality for papillary and follicular carcinomas is similar in patients of comparable age and disease stage. Both cancers have an excellent prognosis if the tumors are confined to the thyroid, are small, and are minimally invasive. Both papillary and follicular carcinomas have far less favorable outcomes if they are highly invasive or develop distant metastases.^{9,63} Note that staging for patients with papillary and follicular carcinoma who are older than 45 years has been revised in the 2002 guidelines (6th edition) from the American Joint Commission on Cancer (AJCC) (see [Table 1](#)).⁶⁴ Many studies (including those discussed in this manuscript) have been based on AJCC-TNM staging from earlier editions, such as the 5th edition⁶⁵ and not the 6th edition.⁶⁴

When Hürthle (oncocytic) cells constitute most or all of a malignant tumor’s mass, the disease is often classified as Hürthle cell carcinoma, although the World Health Organization classification considers it as a variant of follicular carcinoma.⁶⁶ Molecular studies suggest, however, that this tumor may be more similar to papillary than follicular carcinomas.⁶⁷ Benign and malignant Hürthle tumors usually cannot be discriminated by FNA or frozen section examination, although large (>4

cm) tumors are more likely to be malignant than smaller ones.⁶⁸ Hürthle cell carcinomas may be aggressive, especially when vascular invasion or large tumors occur in older patients.^{69,70} Some believe these cancers are not much more aggressive than similarly staged follicular carcinomas without Hürthle cells.⁷¹ In the NCDB report, the 10-year relative survival rates were 85% for follicular carcinomas and 76% for Hürthle cell carcinoma.⁸

In 2 large series, pulmonary metastases occurred in 25% and 35% of patients with Hürthle cell carcinoma, about twice the frequency of follicular carcinoma metastases.^{72,73} Fewer Hürthle cell carcinomas concentrate ¹³¹I than do papillary or follicular carcinomas. The University of Texas M.D. Anderson Cancer Center reported that in a series of 100 patients with distant metastases, ¹³¹I uptake by pulmonary metastases was seen in more than 50% of the follicular (64%) and papillary (60%) carcinomas but in only 36% of Hürthle cell carcinomas.⁷⁴

Primary Tumor Size

Papillary carcinomas smaller than 1 cm, termed “*microcarcinomas*,” are typically found incidentally after surgery for benign thyroid conditions. Their recurrence and cancer-specific mortality rates are near zero.^{75,76}

Other small papillary carcinomas become clinically apparent. For example, about 20% of microcarcinomas are multifocal tumors that commonly metastasize to cervical lymph nodes. Some researchers report a 60% rate of nodal metastases from multifocal microcarcinomas,⁷⁷ which may be the presenting feature and also may be associated with distant metastases.⁷⁶ Otherwise, small (< 1.5 cm) papillary or follicular carcinomas confined to the thyroid almost never cause distant metastases. Furthermore, rates of recurrence after 30 years are one third of those associated with larger tumors; 30-year cancer-specific mortality is 0.4% compared to 7% ($P<.001$) for tumors 1.5 cm or larger.⁹ In fact, the prognosis for papillary and follicular

carcinomas is incrementally poorer as tumors increase in size.^{63,78} There is a linear relationship between tumor size and recurrence or cancer-specific mortality for both papillary and follicular carcinomas (see [Figure 2](#)).⁹

Local Tumor Invasion

Up to 10% of differentiated thyroid carcinomas invade through the outer border of the gland and grow directly into surrounding tissues, increasing both morbidity and mortality. The local invasion may be microscopic or gross; it can occur with both papillary and follicular carcinomas.^{9,79} Recurrence rates are 2 times higher with locally invasive tumors, and as many as 33% of patients with such tumors die of cancer within a decade.^{9,80}

Lymph Node Metastases

In one review, nodal metastases were found in 36% of 8029 adults with papillary carcinoma, in 17% of 1540 patients with follicular carcinoma, and in up to 80% of children with papillary carcinoma.⁴⁰ An enlarged cervical lymph node may be the only sign of thyroid carcinoma. In these patients, multiple nodal metastases are usually found at surgery.⁸¹ The prognostic importance of regional lymph node metastases is controversial. Some studies find that the presence of regional lymph node metastases has no effect on recurrence or survival.⁴⁴⁻⁴⁶ Other studies find that nodal metastases are a risk factor for local tumor recurrence and cancer-specific mortality and that nodal metastases correlate with distant metastases, especially if there are bilateral cervical or mediastinal lymph node metastases or if the tumor invades through the lymph node capsule.^{9,39,82} In one study, 15% of patients with cervical node metastases died of thyroid carcinoma ($P < .02$), whereas all patients without cervical node metastases survived.⁸³ Another study of patients with distant metastases from papillary carcinoma reported that 80% had mediastinal node metastases at the time cancer was diagnosed.⁸⁴ Still another study found that patients with papillary or follicular carcinoma who had cervical or mediastinal

lymph node metastases had a significantly ($P < .01$) higher 30-year cancer-specific mortality (10%) than patients without metastases (6%).⁹

Distant Metastases

Distant metastases are the principal cause of death from papillary and follicular carcinomas. Almost 10% of patients with papillary carcinoma and up to 25% of those with follicular carcinoma develop distant metastases. About 50% of these metastases are present at the time of diagnosis.⁴⁰ Distant metastases occur even more often in patients with Hürthle cell cancer (35%) and in those patients diagnosed after age 40 years.^{72,74} The sites of reported distant metastases among 1231 patients in 13 studies were lung (49%), bone (25%), both lung and bone (15%), and the central nervous system (CNS) or other soft tissues (10%). The main predictors of outcome for patients with distant metastases are patient's age, the tumor's metastatic site, ability to concentrate ¹³¹I, and morphology on chest radiograph.^{72,74,85,86}

Although some patients, especially younger ones, with distant metastases survive for decades, about 50% die within 5 years regardless of tumor histology.⁴⁰ Even so, some pulmonary metastases are compatible with long-term survival. For example, one study found that when distant metastases were confined to the lung, more than 50% of the patients were alive and free of disease at 10 years, whereas no patients with skeletal metastases survived that long.⁸⁷ The survival rates are highest in young patients with diffuse lung metastases seen only on ¹³¹I imaging and not on x-ray,^{86,87} which appears to be the most important feature governing an improved survival rate and prolonged disease-free interval with lung metastases.⁸⁸ Prognosis is worse with large pulmonary metastases that do not concentrate ¹³¹I and is intermediate with small nodular metastases that are seen on radiographs but that do concentrate ¹³¹I.^{72,74,85}

Tumor Staging and Prognostic Scoring Strategies

Several staging and clinical prognostic scoring strategies use patient age older than 40 years as a major feature to identify cancer mortality risk from differentiated thyroid carcinoma.^{38,44,64,89} When applied to the papillary carcinoma data from the Mayo Clinic, 4 of the schemes using age (EORTC [European Organization for Research and Treatment of Cancer], TNM 5th edition [tumor, node, metastasis], AMES [Age, Metastases, Extent, and Size], and AGES [Age, tumor Grade, Extent, and Size]) were effective in separating low-risk patients (in whom the 20-year, cancer-specific mortality was 1%) from high-risk patients (in whom the 20-year, cancer-specific mortality was 30% to 40%).⁷⁸ With incrementally worsening MACIS (Metastasis, Age, Completeness of resection, Invasion, and Size) scores of less than 6, 6 to 6.99, 7 to 7.99, and 8+; however, the 20-year survival rates decreased from 99% to 89%, 56%, and 24%, respectively.⁴⁴ It is noteworthy that only “Completeness of resection” is subject to intervention, and its contribution to prognosis is small.

Unfortunately, a study that classified 269 patients with papillary carcinoma according to 5 different prognostic paradigms found that some patients in the lowest risk group from each approach died of cancer.⁴⁷ This is particularly true of classification schemes that simply categorize patients dichotomously as low or high risk.^{64,90} The AJCC TNM staging approach (see [Table 1](#)), which is perhaps the most widely used indicator of prognosis, classifies tumors in all patients younger than 45 years as stage I or stage II, even those with distant metastases. Although it predicts cancer mortality reasonably well,^{91,92} TNM staging was not established as a predictor of recurrence and therefore does not forecast accurately the recurrences that often occur in patients who develop thyroid cancer when they are young. Currently, no prognostic systems address variants of papillary and follicular carcinoma whose clinical behavior affects outcome. Two studies have

demonstrated the poor predictive value of most staging approaches for thyroid carcinoma, including the TNM system.^{38,93}

Differentiated thyroid cancer staging systems are certainly of value in epidemiology studies and as tools to stratify patients for prospective trials.⁹⁴ Staging systems, which are designed to segregate patients on the basis of survival, offer gross indications of prognosis for groups of patients but probably are of far less utility in determining treatment for individual patients. When treating differentiated thyroid cancer, where most patients do not succumb to cancer, many clinicians have placed a stronger emphasis on potential morbidity than on mortality.

Systems designed to predict survival provide little guidance with respect to morbidity sustained by patients who are likely to be cured by their treatments. Although the TNM classification of the AJCC and International Union Against Cancer (UICC) is universally available and widely accepted for other disease sites, the NCCN Thyroid Carcinoma Guidelines do not use TNM stages to guide therapy. Instead, many tumor and patient characteristics play important roles in these NCCN guidelines. Many specialists in thyroid cancer also follow this paradigm. Several international surveys, including one by the clinical members of the American Thyroid Association, indicate that most clinicians do not factor age into their therapeutic decisions.^{95,96} This view is held by most participants in this NCCN Thyroid Carcinoma Panel.

Surgical Management of Differentiated Thyroid Carcinoma

Ipsilateral Lobectomy Versus Total or Near-Total Thyroidectomy

The continuing debate surrounding the appropriate extent of thyroid resection reflects the limitations of prognostic scoring⁴⁶ and the morbidity often associated with total thyroidectomy performed outside of referral centers. For example, Hay and colleagues reported in 1987 that patients treated at the Mayo Clinic for low-risk papillary thyroid carcinomas (MACIS score 3.99 or less) had no improvement in survival

rates after undergoing procedures more extensive than ipsilateral lobectomy and, accordingly, concluded that more aggressive surgery was indicated only for those with higher MACIS scores.⁹⁷ In 1998, however, that center reported the results of a study designed to compare cancer-specific mortality and recurrence rates after unilateral or bilateral lobectomy. The study involved patients with papillary carcinoma considered to be low risk by AMES criteria.⁹⁸ The investigators found no significant differences in cancer-specific mortality or distant metastasis rates between the 2 groups, but the 20-year frequencies of local recurrence and nodal metastasis after unilateral lobectomy were 14% and 19%, respectively, which were significantly higher ($P = .0001$) than the frequencies of 2% and 6% seen after bilateral thyroid lobe resection. On the basis of these observations, Hay and colleagues concluded that bilateral thyroid resection is the preferable initial surgical approach for patients with AMES low-risk papillary carcinoma.⁹⁸

Most NCCN panel members (and other authors) advise total or near-total thyroidectomy for all patients in whom the diagnosis of thyroid carcinoma is assigned preoperatively,^{12,20,99} because, while they have little influence on deaths from cancer, such procedures are associated with improved disease-free survival, even in children and adults with low-risk tumors.^{35,48,98,100} Some centers report that patients treated by lobectomy alone have a 5% to 10% recurrence rate in the opposite thyroid lobe^{40,97} with an overall long-term recurrence rate of more than 30% (versus 1% after total thyroidectomy and ¹³¹I therapy)⁹ and the highest frequency (11%) of subsequent pulmonary metastases.¹⁰¹ Higher recurrence rates are also observed with cervical lymph node metastases and multicentric tumors, providing some additional justification for more complete initial thyroid resection.⁹ However, some prominent thyroid cancer specialists (including some at NCCN institutions) oppose this view and advocate unilateral lobectomy for most patients with papillary and follicular thyroid carcinoma on the basis

of both the low mortality among those patients categorized as low risk by the AMES and other prognostic classification schemes (ie, most patients) and of the high complication rates reported with more extensive thyroidectomy.^{45,89,102} The large thyroid remnant, however, may complicate long-term follow-up with serum thyroglobulin (Tg) determinations, and it will frustrate whole-body ¹³¹I scans. In most clinical settings, decisions surrounding the extent of thyroidectomy should be individualized and undertaken in consultation with the patient. Circumstances in which unilateral thyroidectomy is inadvisable are detailed in the guidelines.

NCCN panelists believe that total lobectomy alone is adequate treatment for papillary microcarcinomas provided the patient has not been exposed to radiation, has no other risk factors, and has a tumor smaller than 1 cm that is unifocal and confined to the thyroid without vascular invasion.^{9,75,76} The same is true for minimally invasive follicular cancers.

Completion Thyroidectomy

This procedure is recommended when remnant ablation is anticipated or if long-term follow-up with serum Tg determinations with or without whole-body ¹³¹I scans are planned. Large thyroid remnants are difficult to ablate with ¹³¹I.¹⁰¹ Completion thyroidectomy has a comparable net complication rate to that of total thyroidectomy. Some experts recommend completion thyroidectomy for routine treatment of tumors 1 cm or larger, because approximately 50% of patients with cancers this size have additional cancer in the contralateral thyroid lobe.^{79,103-107} In patients with local or distant tumor recurrence after lobectomy, cancer is found in more than 60% of the resected contralateral lobes.¹⁰⁵

Miccoli and colleagues studied irradiated children from Chernobyl who developed thyroid carcinoma and were treated by lobectomy; they found that 61% had unrecognized lung or lymph node metastases that could only be identified after completion thyroidectomy.⁴⁸ In another

study, patients who underwent completion thyroidectomy within 6 months of their primary operation developed significantly fewer lymph node and hematogenous recurrences, and they survived significantly longer than did those in whom the second operation was delayed for more than 6 months.¹⁰⁶

Surgical Complications

The most common significant complications of thyroidectomy are hypoparathyroidism and recurrent laryngeal nerve injury. These complications occur with much higher frequency after total thyroidectomy. Transient clinical hypoparathyroidism after surgery is common in adults¹⁰⁸ and still more common in children^{48,109} undergoing total thyroidectomy. However, the rates of persistent hypocalcemia are reported to be much lower, at least in the hands of experienced thyroid surgeons. In a review of 7 published surgical series, the average rates of long-term recurrent laryngeal nerve injury and hypoparathyroidism, respectively, were 3% and 2.6% after total thyroidectomy, and 1.9% and 0.2% after subtotal thyroidectomy.¹¹⁰ One study reported hypocalcemia in 5.4% of patients immediately after total thyroidectomy, persisting in only 0.5% of patients 1 year later.¹¹¹

When experienced surgeons perform the operations, complications occur at a lower rate. A study of 5860 patients treated in the state of Maryland found that surgeons who performed more than 100 thyroidectomies a year had the lowest overall complication rate (4.3%), whereas surgeons who performed fewer than 10 thyroidectomies a year had 4 times as many complications.¹¹²

Radioactive Iodine

Adjuvant Radioiodine Therapy

Postoperative ¹³¹I thyroid remnant ablation is performed when the patient has a tumor with the potential for recurrence.¹¹³ Studies demonstrate decreased recurrence and disease-specific mortality when postoperative ¹³¹I therapy is administered as part of the initial treatment,

but the supportive data are largely confined to higher risk populations.^{9,39,47,114,115} In a study assessing outcomes in 1004 patients with differentiated thyroid carcinoma, tumor recurrence was about 3-fold higher in patients either treated with thyroid hormone alone or given no postoperative medical therapy when compared with patients who underwent postoperative thyroid remnant ablation with ¹³¹I ($P<.001$). Moreover, fewer patients developed distant metastases ($P<.002$) after thyroid remnant ¹³¹I ablation than after other forms of postoperative treatment; however, this effect is observed only in patients with primary tumors 1.5 cm or more in diameter.¹¹⁴ Some find that remnant ablation has less of a therapeutic effect, perhaps, because more extensive loco-regional surgery had been done.⁷⁸

Debate continues about ablating the thyroid bed with ¹³¹I after near-total thyroidectomy.^{78,114} Proposed mechanisms by which remnant ablation may decrease recurrences and disease-specific mortality include the ablation of normal tissue destined to become malignant, ablation of residual microscopic malignancy in the remnant, ablation of residual microscopic malignancy outside the remnant, ablation of residual malignancy outside the remnant obscured by uptake in a large thyroid remnant, and the demonstration of unsuspected residual malignancy on the post-therapy scan, which alters disease stage and promotes further patient management. Other reasons favoring remnant ablation include (1) simplified patient follow-up, because elimination of “thyroid bed” uptake eliminates misinterpretation of it as disease; (2) remnant ablation eliminates normal tissue as a source of Tg production, which facilitates identification of patients who are free of disease and may simplify their care while promoting early identification of those with residual cancer; and (3) elimination of normal tissue may eliminate the nidus for continued confounding anti-Tg antibody production. However, long-term evaluation of recurrence risk after adjuvant radioiodine may be confounded by the accompanying improved specificity of diagnostic testing after elimination of the thyroid remnant and by the possibility

that patients who receive adjuvant therapy may be more likely to undergo more intensive follow-up testing.

Diagnostic Whole-Body Scans and Thyroid Stunning

Whole-body ¹³¹I scans are often performed after surgery to assess the completeness of thyroidectomy and the presence of residual disease. However, a phenomenon termed “stunning” may occur when scanning doses of ¹³¹I induce follicular cell damage. Stunning decreases uptake in the thyroid remnant or metastases, thus impairing the therapeutic efficacy of subsequent ¹³¹I.¹¹⁶

The use of ¹²³I or small (2 or 3 mCi) doses of ¹³¹I and/or a shortened interval of not more than 72 hours between the diagnostic ¹³¹I dose and the therapy dose has been recommended to avoid or reduce the stunning effect; however ¹²³I is more expensive and smaller ¹³¹I doses have reduced sensitivity when compared with larger ¹³¹I doses.^{116,117} Some experts recommend that diagnostic ¹³¹I scans be avoided completely with decisions based on the combination of tumor stage and serum Tg. Other experts advocate that the whole-body ¹³¹I diagnostic scan may alter therapy, for example: (1) when unsuspected metastases are identified, or (2) when an unexpectedly large remnant is identified that requires additional surgery or a reduction in radioiodine dosage to avoid substantial radiation thyroiditis.¹¹⁸

Administration of Radioiodine Therapy

Historically, the 3 methods of determining ¹³¹I therapy activities (doses) have included: empiric fixed doses, quantitative dosimetry, and upper bound limits that are set by blood dosimetry.¹¹⁹ Recently a fourth method that adjusts the activity to deliver a selected dose to the blood (as a surrogate of the activity available for the remnant or target tissue) has become available using simplified single time point whole body dosimetry (Kloos, personal communication). In the past, hospitalization was required to administer therapeutic doses of ¹³¹I larger than 30 mCi (1110 MBq). However, hospitalization is no longer necessary in most

states, because a change in federal regulations permits the use of much larger ¹³¹I doses in ambulatory patients.¹¹⁹

Fixed ¹³¹I Doses

Administration of a fixed dose of ¹³¹I is the most widely used and simplest method. Most clinics use this method regardless of the percentage uptake of ¹³¹I in the remnant or metastatic lesion. Patients with uptake in tumor are routinely treated with large, fixed amounts of ¹³¹I. Lymph node metastases may be treated with about 100 to 175 mCi (3700 to 6475 MBq) of ¹³¹I. Cancer growing through the thyroid capsule and incompletely resected is treated with 150 to 200 mCi (5550 to 7400 MBq). Patients with distant metastases are usually treated with 200 mCi (7400 MBq) of ¹³¹I, which typically will not induce radiation sickness or produce serious damage to other structures but may exceed generally accepted safety limits to the blood in the elderly and in those with impaired kidney function.^{120,121} Diffuse pulmonary metastases that concentrate 50% or more of the diagnostic dose of ¹³¹I (which is very uncommon) are treated with 150 mCi of ¹³¹I (5550 MBq) or less to avoid lung injury, which may occur when more than 80 mCi remain in the whole body 48 hours after treatment.

Quantitative Tumor ¹³¹I Dosimetry

A second method is to use quantitative dosimetry methods to estimate the amount of radiation delivered to the lesion per unit of ¹³¹I administered. This approach is attractive, because radiation exposure from arbitrarily fixed doses of ¹³¹I can vary substantially. If the calculated dose to the tumor is less than 3500 cGy, it is unlikely that the cancer will respond to ¹³¹I therapy.^{119,122} Radioiodine activities that deliver more than 30,000 cGy to the residual normal tissue and more than 8000 cGy to metastatic foci are likely to be effective. It is necessary to serially measure the radiation activity in the target using a tracer dose and to estimate the tumor size to make these calculations,

which is difficult to do and is impossible in the setting of diffuse or microscopic lung metastases.

Blood ¹³¹I Dosimetry

A third method is to administer a dose calculated to deliver a maximum of 200 cGy to the blood, while keeping the whole-body retention less than 120 mCi (4440 MBq) at 48 hours or less than 80 mCi (2960 MBq) when there is diffuse pulmonary uptake.¹²³ Thyroid cancer dosimetry and radioiodine therapy with doses above 200 mCi are best done in medical centers with experience using these treatments.

Post-Treatment ¹³¹I Scans

When ¹³¹I therapy is given, a whole-body radioiodine scan should be performed several days later to document ¹³¹I uptake by the tumor. The post-treatment whole-body radioiodine scan should be done primarily because up to 25% of such scans show lesions that may be clinically important that were not detected by the diagnostic scan.¹¹⁹ In a study of pre-treatment and post-treatment scans, the 2 differed in 27% of the treatment cycles, but only 10% of the post-treatment scans showed clinically significant new foci of metastatic disease.¹²⁴ Post-treatment scans were most likely to reveal clinically important new information in patients younger than 45 years who had received ¹³¹I therapy in the past. Conversely, in older patients and patients who had not previously received ¹³¹I therapy, the post-treatment scans rarely yielded new information that might have altered the patient's prognosis.¹²⁴ Thus, the NCCN panel only gives a category 2B recommendation for post-treatment radioiodine scanning.

Assessment and Management After Initial Treatment

Serum Tg determinations, neck ultrasound, and whole-body ¹³¹I imaging detect recurrent or residual disease in most patients who have undergone total thyroid ablation.¹²⁵ In contrast, neither serum Tg or whole-body radioiodine imaging is specific for thyroid cancer in patients

who have not undergone thyroidectomy and remnant ablation. When initial ablative therapy has been completed, serum Tg should be measured periodically. Serum Tg can be measured while the patient is taking thyroxine, but the test is more sensitive when thyroxine has been stopped or when recombinant human TSH (rhTSH) is given to increase the serum TSH.^{126,127} Using current Tg assays, patients with measurable serum Tg levels during TSH suppression and those with stimulated Tg levels more than 2 ng/mL are likely to have residual/recurrent disease that may be localized in almost 50% promptly and in an additional 30% over the next 3-5 years.¹²⁸ About 6% of patients with detectable serum Tg levels, which are less than 2 ng/mL after stimulation, have recurrences over the next 3-5 years, while this is true for about 2% of patients with completely undetectable serum Tg after stimulation. Conversely, the long-term clinical significance is uncertain for disease only detected by minimally elevated Tg levels after stimulation.

Recombinant Human TSH

During follow-up, periodic withdrawal of thyroid hormone therapy has traditionally been required to increase the serum TSH concentrations sufficiently to stimulate thyroid tissue so that serum Tg measurements (with or without ¹³¹I scanning) could be performed to detect residual thyroid tissue or carcinoma. An alternative to thyroid hormone withdrawal is the administration of rhTSH intramuscularly, which stimulates thyroidal ¹³¹I uptake and Tg release while the patient continues thyroid hormone suppressive therapy and avoids symptomatic hypothyroidism.¹²⁹

A second multicenter international study was performed to assess the effects of 2 rhTSH dosing schedules on whole-body ¹³¹I scans and serum Tg levels when compared with scans and Tg levels obtained after thyroid hormone withdrawal. The scanning method in this study was more carefully standardized and took into account the fact that ¹³¹I

retention was higher in patients rendered hypothyroid than in patients given rhTSH.¹²⁷ Scans were concordant in 89% of the patients and superior in 4% of the patients after rhTSH and superior in 8% of patients after thyroid hormone withdrawal, but these differences were not statistically significant. The main finding in this study was that the combination of rhTSH–stimulated whole-body scanning and serum Tg measurements detected 100% of metastatic carcinoma.¹²⁷ In this study, 0.9 mg of rhTSH was given intramuscularly every day for 2 days, followed by a minimum of 4 mCi of ¹³¹I on the third day. A whole-body scan and Tg measurements were performed on the fifth day. Whole-body ¹³¹I images were acquired after 30 minutes of scanning or after obtaining 140,000 counts, whichever came first. A serum Tg of 2.0 ng/mL or higher obtained 72 hours after the last rhTSH injection indicates that thyroid tissue or thyroid carcinoma is present, regardless of the whole-body scan findings.^{127,130}

Recombinant human TSH is well tolerated. Nausea (10.5%) and transient mild headache (7.3%) are its main adverse effects.¹²⁷ It is associated with significantly fewer symptoms and dysphoric mood states than hypothyroidism induced by thyroid hormone withdrawal.¹²⁹

Measuring Serum Tg

Serum Tg measurement is the best means of detecting thyroid tissue. Tg should be measured when TSH has been stimulated either by thyroid hormone withdrawal or by rhTSH, when serum Tg has a lower false-negative rate than whole-body ¹³¹I scanning.^{126-128,131,132} Serum Tg levels vary in response to the increase in serum TSH after thyroid hormone withdrawal or rhTSH stimulation. Serum Tg generally does not rise as high after rhTSH administration as after withdrawal of thyroid hormone. The conditions for rhTSH–stimulated whole-body ¹³¹I scans stipulate using 4-mCi ¹³¹I doses (based on the doses used in the pivotal phase III trial)¹²⁷ and a scanning time of 30 minutes or until 140,000 counts are obtained.

The sensitivity and specificity of various Tg assays, however, vary widely in different laboratories, even with the use of an international standard (CRM 457).^{133,134} It is therefore recommended that patients undergo Tg monitoring via the same Tg assay performed in the same laboratory. Ideally, serum is frozen and saved for future analyses if needed, especially should a change in Tg assay be necessary.

Anti-Tg antibodies should be measured in the serum sample taken for Tg assay because these antibodies (which are found in up to 25% of patients with thyroid carcinoma) invalidate serum Tg measurements in most assays.¹³⁵ These antibodies typically falsely lower the Tg value in immunochemiluminometric assay (ICMA) and immunoradiometric (IRMA) assays, while raising the value in older radioimmunoassay (RIA). Although the clinical importance of these antibodies is unclear, their persistence for more than 1 year or so after thyroidectomy and radioiodine ablation probably indicates the presence of residual thyroid tissue and possibly an increased risk of recurrence.¹³⁵ In one study, 49% of patients with undetectable serum Tg concentrations and serum anti-Tg antibody concentrations of 100 U/mL or more had a recurrence when compared with only 3% of patients with undetectable serum Tg concentrations and serum anti-Tg antibody concentrations of less than 100 U/mL.¹³⁶ In patients with co-existent autoimmune thyroid disease at the time of surgery, anti-Tg antibodies may persist far longer. In a study of 116 patients with anti-Tg antibodies before thyroidectomy, antibodies remained detectable for up to 20 years in some patients without detectable thyroid tissue, and the median time to disappearance of antibodies was 3 years.¹³⁷

Heterophile antibodies may falsely increase or decrease serum Tg measurements in the absence of anti-Tg antibodies. Clues to the presence of a false Tg elevation are the lack of Tg rise with TSH stimulation and the lack of linear results with serum sample dilution. Heterophile blocking tubes may be used to correct this problem.

RNA-based detection strategies (including the sodium-iodine symporter [NIS], TSH receptor, and Tg mRNAs) or DNA-based strategies to detect thyroid oncogenes in peripheral blood, represent current areas of active research that may improve the detection of residual cancer and the monitoring of these patients, especially during thyroxine treatment or when circulating anti-Tg antibodies are present.^{138,139}

Treating Tg-Positive/Scan-Negative Patients

Post-treatment ¹³¹I scans may yield localizing information when the serum Tg level is increased, but a tumor cannot be found by physical examination or localizing techniques (such as diagnostic ¹³¹I scans, neck ultrasonography, computed tomography [CT], magnetic resonance imaging [MRI], or PET). Pulmonary metastases may be found only after administering therapeutic doses of ¹³¹I and obtaining a whole-body scan within a few days of treatment.¹⁴⁰ In a study of 283 patients treated with 100 mCi (3700 MBq) of ¹³¹I, 6.4% had lung and bone metastases detected after treatment that had been suspected on the basis of high serum Tg concentrations alone but had not been detected after 2-mCi (74 MBq) diagnostic scans.¹⁴¹

In another study, all but 1 of 17 patients with increased serum Tg concentrations and negative 5-mCi (185 MBq) diagnostic scans showed ¹³¹I uptake after 75 to 140 mCi (2775 to 5180 MBq) of ¹³¹I; more than 50% of these patients had lung metastases.¹⁴²

Unfortunately, most diagnostic scan–negative/Tg-positive patients are not rendered disease free by ¹³¹I therapy; however, the tumor burden may be diminished.¹⁴³ For this reason, most patients with residual or recurrent disease confined to the neck undergo re-operation rather than radioiodine therapy in the hopes of a higher chance for cure.

Radioiodine therapy is more commonly considered for those with distant metastases or inoperable local disease. Patients not benefiting from this therapy can be considered for clinical trials, especially those patients with progressive metastatic disease. When a large tumor is not

visible on a diagnostic whole-body scan, this implies that its ¹³¹I concentrating ability per gram of tissue is very low and hence a lack of response to ¹³¹I therapy may be anticipated.

The Tg level recommended for empiric treatment has been decreasing; it was approximately 30 or 40 ng/mL about a decade ago, but now it is approximately 10 ng/mL.^{140,144} However, no study has yet demonstrated any decrease in morbidity or mortality in patients treated with ¹³¹I on the basis of increased Tg measurements alone. In a long-term follow-up study, no suggestion of a survival advantage was associated with empiric high-dose radioiodine in scan-negative patients.¹⁴⁵ Further, potential long-term side effects (such as xerostomia, nasolacrimal duct stenosis, bone marrow and gonadal compromise, and the risk of hematologic and other malignancies) may negate any benefit.^{113,146}

Thyroid Hormone Suppression of TSH

Decreased recurrence and cancer-specific mortality rates for differentiated thyroid carcinoma are reported by some authors for patients treated with thyroid hormone suppressive therapy.^{9,114,147-151} The average dosage needed to attain serum TSH levels in the euthyroid range is higher in patients with thyroid carcinoma (2.11 mcg/kg per day) than in those patients with spontaneously occurring primary hypothyroidism (1.62 mcg/kg per day)¹⁵⁰ and still higher doses are required to suppress serum TSH in thyroid carcinoma patients. Still, the optimal TSH level to be achieved in patients with thyroid carcinoma is uncertain. Superior outcomes were associated with aggressive thyroid hormone suppression therapy in high-risk patients but were achieved with modest suppression in stage II patients.¹⁵¹ Excessive TSH suppression (into the undetectable, thyrotoxic range) is not required to prevent disease progression in all patients with differentiated thyroid cancer. As a practical matter, the most appropriate dose of thyroid hormone for most low-risk patients with differentiated thyroid carcinoma is the dose that decreases the serum concentration

to just below the lower limit of the normal range for the assay being used. A greater degree of suppression is generally recommended for higher risk patients.

Adjuvant External-Beam Radiation Therapy

No prospective controlled trials have been completed using adjuvant external-beam RT. An attempt to perform such a study encountered marked resistance to randomization among most patients eligible to participate in such a trial.¹⁵² One retrospective study demonstrated a benefit of adjuvant external-beam RT after radioactive iodine in patients older than 40 years who have invasive papillary thyroid cancer (T4) and lymph node involvement (N1).¹⁵³ Local recurrence and locoregional and distant failure were significantly improved. A second study demonstrated improved cause-specific survival and local relapse-free rate in selected patients treated with adjuvant external-beam RT (in addition to total thyroidectomy and TSH-suppressive therapy with thyroid hormone) for papillary thyroid carcinoma with microscopic residuum. Not all patients received radioactive iodine therapy.³⁹ Benefit was not shown in patients with follicular thyroid carcinoma or other subgroups of papillary thyroid carcinoma. Similarly, patients with microscopic residual papillary carcinoma after surgery are more commonly rendered disease free after receiving external RT (90%) than when not receiving it (26%).¹⁵⁴ In another study, patients with microscopically invasive follicular carcinoma after surgery were also more often disease free when postoperative external RT is given (53%) than when it is not given (38%).¹⁵⁴ However, these patients had not received radioactive iodine. Similar benefit was shown with radioactive iodine alone in comparable patients treated with radioactive iodine after surgery.¹⁵⁴

Chemotherapy, External-Beam Radiation, and Surgical Excision of Metastases

Focal lesions that do not concentrate ¹³¹I adequately and isolated skeletal metastases should be considered for surgical excision or

external irradiation. Brain metastases pose a special problem, because ¹³¹I therapy may induce cerebral edema. Once brain metastases are diagnosed, disease-specific mortality is very high (67%), with a reported median survival of 12.4 months in one retrospective study. Survival was significantly improved by surgical resection of one or more tumor foci.¹⁵⁵

Life-threatening tumors refractory to all other forms of therapy may be palliatively treated with doxorubicin, although the response rate is poor.⁴⁰ The experience with chemotherapy in patients with differentiated thyroid carcinoma is limited, because most recurrent tumors respond well to surgery, ¹³¹I therapy, or external-beam RT. Chemotherapy's main use has been for tumors that are not surgically resectable, are not responsive to ¹³¹I, and have either been treated with or are not amenable to therapy with external-beam RT. Among 49 patients with metastatic differentiated thyroid carcinoma who were treated with 5 chemotherapy protocols, only 2 (3%) patients had objective responses.¹⁵⁶ In a review of published series, 38% of patients had a response (defined as a decrease in tumor mass) to doxorubicin.¹⁵⁷ Combination chemotherapy is not clearly superior to doxorubicin therapy alone.⁴⁰ Overall, traditional cytotoxic systemic chemotherapy (eg, doxorubicin) has minimal efficacy in patients with metastatic differentiated thyroid disease.

Several phase II trials have been initiated to evaluate novel treatments for patients with metastatic differentiated thyroid carcinoma. The first to be completed and published was a phase II study of celecoxib (400 mg twice daily) in patients with progressive, radioiodine-unresponsive disease.¹⁵⁸ Although 12-month progression-free survival was only 3%, 38% of the patients had stable disease, representing a possible alteration in their disease course. Currently, other agents are in clinical trials, including (1) multitargeted kinase inhibitors, such as motesanib diphosphate (AMG-706),^{159,160} sorafenib,^{161,162} sunitinib,¹⁶³ axitinib,¹⁶⁴

and vandetanib; (2) the histone deacetylase inhibitors, vorinostat and depsipeptide; (3) the DNA methylation inhibitor, decitabine; (4) the heat-shock protein 90 (HSP-90) inhibitor, 17-allylamino-17-demethoxygeldanamycin (17-AAG); (5) the proteasome inhibitor, bortezomib; and (6) a derivative of thalidomide, lenalidomide.^{165,166}

Papillary Thyroid Carcinoma

Surgical Therapy

A CT/MRI should be performed if the lesion is fixed or substernal (iodinated contrast should be avoided unless essential). A thyroid ultrasound is recommended if not previously done. A lateral neck ultrasound can also be considered (category 2B). In one report, cervical ultrasound performed before primary surgery for newly diagnosed disease identified metastatic sites not appreciated on physical examination in 20% of patients, and surgical strategy was altered in many patients.¹⁶⁷ A chest x-ray can be considered. The recommendation from the guidelines panel to evaluate vocal cord mobility was one of nonuniform consensus (category 2B).

The panel members agreed on the characteristics of patients who require total thyroidectomy and neck dissection (if lymph nodes are palpable or biopsy positive) as the primary treatment. However, there was not uniform consensus about the preferred primary surgery for patients who are assumed to be at lower risk of cancer-specific mortality. The majority of panel members opted for total thyroidectomy (category 2B) in any patient in whom papillary thyroid carcinoma was identified preoperatively or at the time of surgery. However, a minority of panel members felt strongly that, initially, lobectomy plus isthmusectomy (category 2B) is adequate surgery for patients at lower risk. A study in more than 5000 patients found that survival of patients after partial thyroidectomy was similar to the survival after total thyroidectomy for both low- and high-risk patients.¹⁶⁸ For patients who undergo lobectomy plus isthmusectomy (lower risk patients),

completion of thyroidectomy is warranted for aggressive variant disease, macroscopic multifocal disease, positive isthmus margins, cervical lymph node metastases, or extrathyroidal extension. Note that *aggressive variant disease* is defined as tall cell, columnar cell, insular, oxyphilic, or poorly differentiated features.

The panel agreed that completion of thyroidectomy is appropriate for any large tumor (> 4 cm), positive margins, or gross extrathyroidal invasion (T3 or T4). Incidentally discovered papillary carcinomas 1 cm or more in size may warrant a completion thyroidectomy (category 2B) for a clinically suspicious lymph node, contralateral lesion, or perithyroidal node; an aggressive variant; or macroscopic multifocal disease; Tg measurement plus anti-Tg antibodies is an alternative option to completion thyroidectomy in these patients. Lobectomy is sufficient for tumors resected with negative margins, no contralateral lesion, no suspicious lymph node, or small (< 1 cm) papillary carcinomas found incidentally on the final pathology sections in the course of thyroid surgery for benign disease; Tg measurement plus anti-Tg antibodies may be considered for surveillance for tumors with these features. Thyroxine therapy to reduce serum TSH to low or low normal concentrations is recommended for these patients.

Radioactive Iodine

Postoperative Whole-Body ¹³¹I Diagnostic Scans

Performing a diagnostic whole-body ¹³¹I scan with adequate TSH stimulation (thyroid withdrawal or rhTSH stimulation) before ¹³¹I therapy is a category 2B recommendation. The panel advises that this decision should be weighed against the problem of stunning that occurs with diagnostic ¹³¹I scans.¹⁶⁹ A diagnostic whole-body ¹²³I scan does not carry a risk of stunning. The alternatives to performing a diagnostic ¹³¹I scan are to obtain an ¹²³I scan before ¹³¹I therapy, obtain a thyroid uptake measurement with microcurie quantities of radioiodine to confirm neck uptake, or forgo the diagnostic scan. If radioiodine is

administered after a diagnostic ¹³¹I study, the time interval between radioiodine doses should be minimized. Whenever therapeutic radioiodine is administered, a whole-body scan should be obtained about 5 to 8 days after treatment with ¹³¹I, which is termed a “post-treatment ¹³¹I scan” in the guidelines.

Thyroid Remnant Ablation With Radioactive Iodine

The decision to ablate uptake in the thyroid bed is closely linked to the extent of thyroid surgery and is not recommended for patients who have undergone lobectomy or lobectomy plus isthmusectomy as initial surgery. Panel members debated about the use of ¹³¹I to ablate uptake in the thyroid bed after total thyroidectomy. Ablation may be appropriate for patients after thyroidectomy if they have nodal metastases, distant metastases, aggressive histology, or their initial lesion was 1 cm or more in size. There was nonuniform consensus (category 2B) for adjuvant radioiodine ablation (30-100 mCi) of the thyroid bed for suspected (based on pathology, postoperative Tg, and intraoperative findings) or proven thyroid bed uptake in patients who have had total thyroidectomy. Empiric administration of radioiodine without a diagnostic scan is not routinely recommended by the NCCN panel.

Radioactive Iodine Treatment

Therapy with ¹³¹I is advised for patients with tumors found on examination, imaging studies, or by increased serum Tg levels if these tumors are not amenable to surgical removal and if they concentrate ¹³¹I. Palpable neck disease should be surgically resected before any radioiodine treatment. A negative pregnancy test is required before the administration of radioiodine in women of child-bearing potential. The panel agrees that radioiodine treatment is not needed for patients with Tg levels less than 1 ng/mL, negative radioiodine scans, and negative anti-Tg antibodies. For patients with suspected or proven radioiodine avid residual tumor, radioiodine treatment can be given at 100 to 200 mCi along with a post-treatment scan or dosimetry can be considered for distant metastases.

For unresectable locoregional recurrence, radioiodine treatment with RT can be given if the radioiodine scan is positive; RT alone is another option in the absence of radioiodine uptake. When recurrent disease is suspected based on a high serum stimulated Tg values (more than 10 ng/mL) and based on negative imaging studies (including PET scans), radioiodine therapy can be considered (category 3) using an empiric fixed dose of 100 to 150 mCi of ¹³¹I; however, there was major disagreement about this recommendation. For patients with metastatic disease that is not locoregional, the panel recommends individualized treatment based on the tumor location(s) (eg, solitary CNS, bone, or other extracervical sites).

Adjuvant External-Beam Radiation Therapy

The guidelines recommend that external RT be considered for patients older than 45 years with T4 (surgically evident extra-thyroidal invasion) and without gross residual disease in their neck.

Thyroxine Suppression of TSH

Thyroxine therapy is required after total thyroid resection, and it is advisable even after lobectomy and isthmusectomy. The level of TSH suppression is not stipulated, because data are conflicting on this point. As a practical matter, the most appropriate dose of thyroid hormone for most low-risk patients with differentiated thyroid cancer is a dose that decreases the serum TSH concentration to just below the lower limit of the normal range. At a minimum, patients should not be permitted to have increased TSH levels, because this would represent inadequate treatment of both postsurgical hypothyroidism and differentiated thyroid carcinoma. A greater degree of TSH suppression is generally recommended for higher risk patients, including those with metastatic disease.

Surveillance and Maintenance

Patients should receive an annual follow-up radioiodine scan until no radioactive iodine avid tumor is evident if they have detectable Tg, distant metastases, or soft tissue invasion on initial staging. Low-risk, stage I and II patients no longer require routine radioiodine scans if they have negative stimulated Tg, negative neck ultrasound, and no longer have clinical disease. A subgroup of very low-risk patients (micropapillary carcinomas entirely confined to the thyroid gland) may only require periodic ultrasound followup, without stimulated Tg or followup whole-body scanning, as long as the basal Tg remains low. The guidelines recommend the following: (1) long-term surveillance and maintenance with a physical examination, TSH, Tg, and anti-Tg antibodies measurements every 6 to 12 months, then annually if patients remain disease free; (2) periodic neck ultrasound; (3) TSH–stimulated Tg at 12 months (without radioiodine scan) in patients previously treated with radioiodine with recent negative neck ultrasound and with undetectable TSH-suppressed Tg (anti-Tg antibody negative) with T1-2, N0-1, M0 on initial staging; (4) regular diagnostic whole-body ¹³¹I scans every 12 months until no response is seen to radioiodine treatment in iodine avid tumors (either withdrawal of thyroid hormone or rhTSH) for patients with detectable Tg, distant metastases, or soft tissue invasion on initial staging; and (5) consider additional nonradioiodine imaging for patients whose ¹³¹I scans are negative and stimulated Tg is more than 2 to 5 ng/mL (eg, FDG PET with or without CT if Tg levels are 10 ng/mL or more). The panel acknowledges that the suggested Tg cutoff levels will continue to evolve as new Tg assays are introduced.

Recurrent and Metastatic Disease

The panel agrees that the preferred therapy for recurrent disease is surgery if the tumor can be localized and is resectable. For unresectable locoregional recurrences, ¹³¹I therapy is recommended for tumors that concentrate ¹³¹I (that is, radioiodine scan positive), and

external-beam RT alone is recommended for those that do not concentrate ¹³¹I (that is, radioiodine scan negative). Unresectable iodine avid locoregional disease that is unlikely to respond to radioiodine therapy alone may additionally be treated with external-beam RT. For extra-cervical metastatic disease, several therapeutic approaches are recommended, depending on the site and number of tumor foci. For skeletal metastases, surgical palliation is recommended for symptomatic or asymptomatic tumors in weight-bearing extremities; other therapeutic options are ¹³¹I treatment (if the whole-body scan is positive) with consideration of dosimetry to maximize dosing and/or external-beam RT. Intravenous bisphosphonate (pamidronate or zoledronic acid) therapy may be considered for symptomatic bone metastases; embolization of metastases can also be considered.¹⁷⁰ For metastases to the CNS, neurosurgical resection should be considered for appropriate cases, and/or radioiodine treatment (with rhTSH and steroid prophylaxis) if the radioiodine scan is positive (with consideration of dosimetry to maximize dosing), and/or image-guided RT (see [NCCN Central Nervous System Cancers](#)). For solitary CNS lesions, either neurosurgical resection or stereotactic radiosurgery is preferred. For other extracervical sites, surgical resection of selected, enlarging, or symptomatic metastases can be considered; for other disseminated tumors, ¹³¹I is recommended if the tumor concentrates the radioisotope (with consideration of dosimetry to maximize the dosing), systemic therapy if the patient is not in a clinical trial, or best supportive care.¹⁷¹ Because chemotherapy has been generally disappointing, the guidelines recommend clinical trials for non-radioiodine avid tumors reserving sorafenib or traditional cytotoxic systemic therapy for progressive or symptomatic disease if a trial is not available.^{20,161,162} There are several agents in clinical trials (www.thyroidtrials.org, <http://www.nci.nih.gov/clinicaltrials>).

Follicular Thyroid Carcinoma

Because the diagnosis and treatment of papillary and follicular carcinoma are similar, only the important differences in the management of follicular carcinoma are highlighted. FNA is not as specific for follicular thyroid carcinoma as it is for papillary carcinoma and accounts for the main differences in management of the 2 tumor types. The FNA cytologic diagnosis of “follicular neoplasm” will prove to be a benign follicular adenoma in 80% of cases. However, 20% of patients with “follicular neoplasms” are ultimately diagnosed with follicular thyroid carcinoma when the final pathology is assessed. Further diagnostic and treatment decisions for patients who present with follicular neoplasms are based on their TSH levels. The diagnosis of follicular carcinoma requires evidence for transcapsular nodule invasion or vascular invasion. Because most patients with “follicular neoplasms” have benign disease, total thyroidectomy is recommended only if invasive cancer or metastatic disease is apparent at the time of surgery or if the patient opts for total thyroidectomy to avoid a second procedure if cancer is found at pathologic review. Otherwise, lobectomy plus isthmusectomy is advised as the initial surgery. If invasive follicular carcinoma (extensive vascular invasion) is found on the final histologic sections after lobectomy plus isthmusectomy, prompt completion of thyroidectomy is recommended.

Completion thyroidectomy should be considered for tumors that, on final histologic sections after lobectomy plus isthmusectomy, are minimally invasive follicular carcinomas. *Minimally invasive* cancer is characterized as a well-defined tumor with microscopic capsular and/or a few foci of vascular invasion and often requires examination of at least 10 histologic sections.¹⁷² These tumors may also be simply followed carefully, because minimally invasive follicular carcinomas have an excellent prognosis. However, deaths attributed to minimally invasive follicular carcinoma do occasionally occur. For patients who

have a central neck recurrence, preoperative vocal cord assessment should be considered.

The other features of management and follow-up for follicular carcinoma are identical to those of papillary carcinoma with the exception that adjuvant RT is not used as an adjuvant measure postoperatively for advanced lesions (ie, T4). However, RT is used for nonresectable growing disease in the neck. As is done for papillary carcinoma, adjuvant radioiodine ablation of the thyroid bed (category 2B) can be used for suspected or proven thyroid bed uptake. Radioiodine treatment and post-treatment scan (with consideration of dosimetry for distant metastasis) may be administered for suspected or proven radioiodine avid residual tumor. The decision to perform a diagnostic whole-body ¹³¹I scan with adequate TSH stimulation (thyroid withdrawal or rhTSH stimulation) before ¹³¹I therapy is administered is a category 2B recommendation for both follicular and papillary carcinoma.

Hürthle Cell Carcinoma

This tumor (also known as oxyphilic cell carcinoma) is usually assumed to be a variant of follicular thyroid carcinoma, although the prognosis of Hürthle cell carcinoma is worse.^{173,174} The Hürthle cell variant of papillary carcinoma is rare and seems to have a prognosis similar to follicular thyroid carcinoma.¹⁷⁵ The management of this Hürthle cell carcinoma is almost identical to follicular carcinoma, except that (1) locoregional nodal metastases occur frequently, and therefore therapeutic compartment lymph node dissections may be needed, or prophylactic (category 2B) central neck compartment dissection may be considered; and (2) metastatic Hürthle cell tumors are less likely to concentrate ¹³¹I. For patients who have a central neck recurrence, preoperative vocal cord assessment should be considered.

Adjuvant RT can be considered postoperatively for advanced Hürthle lesions (ie, T4), similar to the management for papillary carcinoma. Nonetheless, adjuvant radioiodine therapy has been reported to decrease the risk of locoregional recurrence and is recommended for unresectable disease with positive radioiodine scans. Radioiodine therapy (100-150 mCi) should be considered (category 2B) after thyroidectomy for patients with stimulated Tg levels of more than 10 ng/mL and scan negative (including FDG-PET).⁷⁰ The panel recommends (category 2B) that a diagnostic whole-body ¹³¹I scan with adequate TSH stimulation (thyroid withdrawal or rhTSH stimulation) be performed before ¹³¹I therapy is administered. Postoperative RT may be used for advanced lesions.

Medullary Thyroid Carcinoma

Medullary thyroid carcinoma (MTC) derives from the neuroendocrine parafollicular or C cells of the thyroid.¹⁷⁶ Sporadic MTC accounts for 80% of all cases of the disease. The remaining cases consist of inherited tumor syndromes, such as multiple endocrine neoplasia type 2A (MEN 2A), MEN 2B, or familial MTC.^{177,178} Because the C cells are predominantly located in the upper portion of each thyroid lobe, patients with sporadic disease typically present with upper pole nodules. Metastatic cervical adenopathy appears in about 50% of patients at initial presentation. Symptoms of upper aerodigestive tract compression or invasion are reported by up to 15% of patients with sporadic disease.¹⁷⁹

Symptoms from distant metastases in lungs or bones occur in 5% to 10% of patients. The ability of the tumor to secrete measurable quantities of calcitonin, occasionally along with other hormonally active peptides (such as adrenocorticotrophic hormone [ACTH] or calcitonin-gene related peptide [CGRP]), can contribute to the development of diarrhea, Cushing's syndrome, or facial flushing in many patients with advanced disease. Sporadic disease typically presents in the fifth or

sixth decade. Familial forms of the disease tend to present at earlier ages, and the risk of concomitant or subsequent development of pheochromocytoma and hyperparathyroidism must always be considered.

Nodule Evaluation and Diagnosis

Patients with medullary carcinoma can be identified by using pathologic diagnosis or by prospective genetic screening. Separate paths are included in the guidelines algorithm depending on the method of identification used.

Sporadic MTC is usually suspected after FNA of a solitary nodule. Routine measurement of the serum calcitonin concentration is not recommended as a screen for MTC in a patient with a solitary nodule. However, reports suggest that perhaps as many as 3% of patients with nodular thyroid disease will have an increased serum calcitonin level when measured by a sensitive immunometric assay; 40% of these patients will prove to have MTC at thyroidectomy.¹⁸⁰⁻¹⁸² Routine measurement of the serum calcitonin concentration is not recommended for evaluating a patient with nodular thyroid disease because of the expense of screening the many existing thyroid nodules to find the few cases of MTC, the lack of confirmatory pentagastrin stimulation testing, and the resulting need for thyroidectomy in some patients who will ultimately be found to have benign thyroid disease.^{183,184}

For patients in known kindreds with inherited MTC, prospective family screening with testing for mutant ret genes can identify disease carriers long before clinical symptoms or signs are noted.¹⁸⁵ The traditional approach of stimulating secretion of calcitonin by either pentagastrin or calcium infusion is no longer recommended, because elevated calcitonin is not a specific or adequately sensitive marker for MTC¹⁸⁶ and because pentagastrin is no longer available in the United States.

Serum intact parathyroid hormone levels and calcium levels are measured when inherited disease is suspected. Compared with sporadic disease, the typical age of presentation for familial disease is the third decade, without gender preference. In MEN 2A, signs or symptoms of hyperparathyroidism or pheochromocytoma rarely present before those of MTC, even in the absence of screening. All familial forms of MTC and MEN 2 are inherited in an autosomal dominant fashion.

Mutations in the *RET* proto-oncogene are found in at least 95% of kindreds with MEN 2A and 88% of familial MTC.^{185,187} The *RET* proto-oncogene codes for a cell membrane-associated tyrosine kinase receptor for a glial, cell line-derived neurotrophic factor. Mutations associated with MEN 2A and familial MTC have been primarily identified in several codons of the cysteine-rich extracellular domains of exons 10, 11, and 13, whereas MEN 2B and some familial MTC mutations are found within the intracellular exons 14-16 (see [Table 2](#)). Somatic mutations in exons 11, 13, and 16 have also been found in at least 25% of sporadic MTC tumors, particularly the codon 918 mutation that activates the tyrosine kinase function of the receptor and is associated with poorer patient prognosis. About 6% of patients with clinically sporadic MTC carry a germline mutation in *RET*, leading to identification of new kindreds with multiple previously undiagnosed affected individuals.¹⁸⁸ Genetic testing for *RET* proto-oncogene mutations should be encouraged for all newly diagnosed patients with clinically apparent sporadic MTC, and for screening children and adults in known kindreds with inherited forms of MTC; genetic counseling should be considered.

Generally accepted approaches to preoperative workup include measurement of serum markers (calcitonin and serum carcinoembryonic antigen [CEA]) and screening patients with germline *RET* proto-oncogene mutations for pheochromocytoma (MEN 2A and

2B) and for hyperparathyroidism (MEN 2A). Before undertaking surgical therapy for MTC, it is important to diagnose and prospectively treat co-existing pheochromocytoma (using alpha-adrenergic blockade [phenoxybenzamine] with or without alpha-methyltyrosine) to avoid hypertensive crisis during surgery. Contrast-enhanced CT of the chest and mediastinum can be considered. Vocal cord mobility should also be evaluated (category 2B). Preoperative neck ultrasound can be considered in adults with clinical disease to evaluate for locoregional adenopathy, but the panel disagreed regarding its use in young patients identified by prospective genetic screening, in whom the frequency of nodal metastases is quite low.

Staging

Compared with differentiated thyroid carcinoma, a smaller set of staging approaches exist for MTC. The TNM criteria for clinicopathologic tumor staging are based on tumor size, the presence or absence of extrathyroidal invasion, locoregional nodal metastases, and distant metastases (see [Table 1](#)) (6th edition AJCC staging manual).⁶⁴ An MTC less than 2 cm in diameter without evidence of disease outside of the thyroid gland is classified as stage I. Any larger tumor (more than 2 cm but 4 cm or less) limited to the thyroid without nodal or distant metastases is classified as stage II. The presence of level 6 nodal metastases, minimal extrathyroidal invasion, or tumor size greater than 4 cm places the patient in stage III. Tumor extending beyond the perithyroid soft tissues, involving lymph nodes beyond level 6, or spreading to distant metastatic sites is classified as stage IV.

Note that all follow-up studies (discussed in this manuscript) reporting on AJCC-TNM staging have referred to the 5th edition⁶⁵ and not the 6th edition.⁶⁴ In one study with a median follow-up period of only 4 years, mortality from MTC was 0% for stage I, 13% for stage II, 56% for stage III, and 100% for stage IV disease.¹⁸⁹ An alternative staging classification proposed by DeGroot defines stage I disease as localized

to the thyroid and stage II as limited to the thyroid or locoregional nodes.¹⁹⁰ Extrathyroidal or extranodal extension characterizes stage III disease, and distant metastases characterize stage IV. Using this approach, survival significantly declines with increasing stage assignment. In particular, the presence of either stage III or stage IV disease increases the risk of death from MTC at least 7-fold and carries a median disease-specific survival of 3 to 5 years.¹⁷⁹ A third approach, used by the National Thyroid Cancer Treatment Cooperative Study Group,³⁸ defines stage I disease as the premalignant lesion C-cell hyperplasia, generally only identified as an incidental finding except as a result of familial screening. Stage II disease is a primary tumor less than 1 cm without locoregional or distant metastasis. Stage III is a tumor greater than 1 cm or locoregional nodal metastasis. The presence of distant metastases defines stage IV disease.

However, these staging classifications lack other important prognostic factors. Notably absent is the age at diagnosis. Patients younger than 40 years at diagnosis have a 5- and 10-year disease-specific survival rate of about 95% and 75%, respectively, compared with 65% and 50% for those older than 40 years.¹⁷⁹ Controlling for the effect of age at diagnosis, the prognosis of patients with inherited disease (who typically are diagnosed at an earlier age) is probably similar to those with sporadic disease.^{191,192} Despite an even younger typical age at diagnosis; however, patients with MEN 2B who have MTC are more likely than those with either MEN 2A or familial MTC to have locally aggressive disease.¹⁹² Other factors that may be important for predicting a worse prognosis include: (1) the heterogeneity and paucity of calcitonin immunostaining of the tumor;¹⁹³ (2) a rapidly increasing CEA level, particularly in the setting of a stable calcitonin level;¹⁹⁴ and (3) postoperative residual hypercalcitoninemia.¹⁸⁹ Improvement in the predictive value of the TNM staging may result from incorporation of disease type (sporadic versus familial) and the presence of bilateral versus unilateral adenopathy.¹⁹⁵ With more study, specific germline or

somatic mutations in *RET* may also be useful predictors of disease outcome. Certainly, presence of an exon 16 mutation, either within a sporadic tumor or associated with MEN 2B, is associated with more aggressive disease.¹⁹⁶

Surgical Management

Surgery is the main treatment for MTC, because there is no known curative systemic therapy for medullary carcinoma. MTC cells do not concentrate radioactive iodine, and MTC does not respond well to conventional cytotoxic chemotherapy or TSH suppression. Even with patients who have apparently sporadic disease, the possibility of MEN 2 should dictate that a *RET* proto-oncogene mutation is proven to be absent or that hyperparathyroidism and pheochromocytoma should be excluded preoperatively. Total thyroidectomy and bilateral central neck dissection (level VI) are indicated in all patients with MTC.¹⁷⁹ If a patient with inherited disease is diagnosed early enough, the recommendation is generally to perform a prophylactic total thyroidectomy by age 5 years, especially in patients with codon 609, 611, 618, 620, 630, or 634 *RET* (risk level II) mutations.¹⁹⁷ Total thyroidectomy is recommended in the first year of life or at diagnosis for MEN 2B patients or carriers of codon 883, 918, or 922 *RET* (risk level III) mutations. However, for patients with codon 768, 790, 791, 891, and 804 *RET* (risk level I) mutations, the lethality of MTC may be lower than with other *RET* mutations.¹⁹⁸ In patients with these *RET* mutations, annual provocative (calcium) calcitonin testing may be performed; total thyroidectomy and central node dissection may be deferred until tests become abnormal after the age of 5 years.¹⁹⁹ Delaying thyroidectomy until age 10 years may also be appropriate for children with risk level I mutations because of the late onset of MTC development.²⁰⁰ A study found no evidence of persistent or recurrent MTC 5 years or more after prophylactic total thyroidectomy in young patients with *RET* mutations for MEN 2A; longer follow-up is necessary to determine if these patients are cured.²⁰¹ Patients with pheochromocytomas must be treated

preoperatively with alpha-adrenergic blockade (phenoxybenzamine) or with alpha-methyltyrosine to avoid a hypertensive crisis during surgery on the thyroid. Forced hydration and alpha-blockade are necessary to prevent hypotension after the tumor is removed. After institution of alpha-blockade and hydration, beta-adrenergic blockade may be necessary to treat tachyarrhythmia.

Variations in surgical strategy for MTC depend on the risk for locoregional node metastases and incorporation of simultaneous parathyroid resection for hyperparathyroidism. A bilateral central neck dissection (level VI) is preferred for all patients with pathologically demonstrated MTC and for those with MEN 2B. For those patients with MEN 2A who undergo prophylactic thyroidectomy, bilateral central neck dissection (level VI) should be considered if patients have an increased calcium-stimulated calcitonin test or if ultrasound shows a thyroid or nodal abnormality. Similarly, more extensive lymph node dissection (levels II to V) is considered for these patients with primary tumor(s) 1 cm or larger in diameter (> 0.5 cm for patients with MEN 2B) or for patients with central compartment lymph node metastases. With a concurrent diagnosis of hyperparathyroidism in MEN 2A, the surgeon should leave or autotransplant the equivalent mass of one normal parathyroid gland if multiglandular hyperplasia is present.

Cryopreservation of resected parathyroid tissue should be considered to allow future implantation in the event of iatrogenic hypoparathyroidism. Disfiguring radical node dissections do not improve prognosis and are not indicated. In the presence of grossly invasive disease, more extended procedures with resection of involved neck structures may be appropriate. Function-preserving approaches are preferred. Postoperative thyroid hormone therapy is indicated; however, TSH suppression is not appropriate, because C cells lack TSH receptors.

Adjuvant Radiation Therapy

External-beam RT has not been adequately studied as adjuvant therapy in medullary carcinoma. Slight improvements have been reported in local disease-free survival after external-beam RT for selected patients, such as those with extrathyroidal invasion or extensive locoregional node involvement. However, most centers do not have extensive experience with adjuvant RT for this disease. When external-beam RT is used, 40 Gy is typically administered in 20 fractions to the cervical, supraclavicular, and upper mediastinal lymph nodes over 4 weeks, with subsequent booster doses of 10 Gy in 5 fractions to the thyroid bed.¹¹⁹ Adjuvant RT can be considered for patients with T4 disease whose tumors are 1.0 cm or more in diameter. As for differentiated carcinoma, external-beam RT can also be given to palliate painful or progressing bone metastases.

Persistently Increased Calcitonin

Serum concentrations of calcitonin and CEA should be measured 2 or 3 months postoperatively. About 80% of patients with palpable MTC and 50% of those with nonpalpable but macroscopic MTC who undergo supposedly curative resection have serum calcitonin values indicative of residual disease. Those patients with residual disease may benefit from further evaluation to detect either residual resectable disease in the neck or the presence of distant metastases. Patients with a basal serum calcitonin value greater than 1000 pg/mL and with no obvious MTC in the neck and upper mediastinum probably have distant metastases, most likely in the liver. However, occasionally patients have relatively low serum CEA and calcitonin levels but have extensive metastatic disease; initial postoperative staging imaging is therefore not unreasonable despite the absence of very high serum markers.

The prognosis for patients with postoperative hypercalcitoninemia depends primarily on the extent of disease at the time of initial surgery. In a study of 31 patients (10 patients with apparently sporadic disease,

15 patients with MEN 2A, and 6 patients with MEN 2B), the 5- and 10-year survival rates were 90% and 86%, respectively.²⁰² Two studies have reported higher mortality rates for patients with high postoperative serum calcitonin values, with more than 50% of patients having a recurrence during a mean follow-up of 10 years.^{189,203} Routine lymphadenectomy or excision of palpable tumor generally fails to normalize the serum calcitonin concentrations in such patients; therefore, some have focused attention on detection and eradication of microscopic tumor deposits with a curative intent in patients without distant metastases. Extensive dissection to remove all nodal and perinodal tissue from the neck and upper mediastinum was first reported to normalize the stimulated serum calcitonin levels in 4 of 11 patients at least 2 years postoperatively.²⁰⁴ In subsequent larger studies, 20% to 40% of patients undergoing microdissection of the central and bilateral neck compartments were biochemically cured, with minimal perioperative morbidity.^{205,206}

When repeat surgery is planned for curative intent, preoperative assessment should include locoregional imaging (such as ultrasonography of the neck and upper mediastinum) and attempts to exclude patients with distant metastases, which may include CT of the chest, and CT or MRI of the abdomen. Laparoscopic assessment of the liver may be performed if distant metastases are not detected by this diagnostic approach.²⁰⁶ However, in the absence of long-term outcomes, application of this approach should probably be limited to those centers with experience with these patients. Other imaging procedures occasionally used include bone scintigraphy; ¹¹¹In-pentetreotide, 6-¹⁸F-fluorodopamine, and ¹⁸F-FDG positron emission tomography; ^{99m}Tc penta-valent dimercaptosuccinic acid, ^{99m}Tc-sestamibi, or tetrofosmin; and systemic venous sampling by catheterization of the hepatic veins, both internal jugular veins, and the innominate veins, with measurements of serum calcitonin before and after stimulation.

Postoperative Management and Surveillance

Measurements of serum calcitonin and CEA levels are the cornerstone of postoperative assessment for residual disease. For patients with a negative calcitonin level, neck ultrasound could be considered. Patients with undetectable calcitonin levels can subsequently be followed with annual measurements of serum markers and additional studies or more frequent testing as indicated. Nonetheless, the likelihood of significant residual disease is very low in patients with a negative basal calcitonin level in a sensitive assay. If the patient has MEN 2, annual screening for pheochromocytoma (MEN 2B or 2A) and hyperparathyroidism (MEN 2A) should also be performed. For some *RET* mutations (eg, codons 768, 790, V804M, or 891), less frequent screening may be appropriate. Patients with abnormal serum markers should be considered for additional diagnostic imaging to identify the location of tumor. The panel recognizes that many different imaging modalities may be used to examine for residual or metastatic tumor, but there is insufficient evidence to recommend any particular choice or combination of tests.

For the asymptomatic patient with abnormal markers in whom imaging fails to identify foci of disease, the panel recommends conservative annual surveillance with repeat measurement of the serum markers. Neck ultrasound scanning may be considered to examine the superior mediastinum, the bilateral central compartment, and the bilateral lateral neck compartments. For asymptomatic patients with abnormal markers and repeated negative imaging, continued observation or consideration of cervical re-operation is recommended if incomplete primary surgery was performed. For the patient with increasing serum markers, more frequent imaging may be considered. Outside of clinical trials, no therapeutic intervention is recommended on the basis of abnormal markers alone.

Recurrent or Persistent Disease

When locoregional disease is identified in the absence of distant metastases, surgical resection is recommended with or without RT. If there is symptomatic progressive and unresectable locoregional disease, then RT is recommended. In the presence of distant metastases, palliative resection may be considered. Similarly, distant metastases that are causing symptoms (such as those in bone) could be considered for palliative resection, ablation (for example, radiofrequency, embolization, or other regional therapy) or other regional treatment. These interventions may be considered for asymptomatic distant metastases (especially for progressive disease) but observation is acceptable, given the lack of data regarding alteration in outcome. In the setting of disseminated distant symptomatic metastases, the guidelines recommend the following: (1) clinical trial (preferred); (2) RT can be administered in the setting of focal symptoms; (3) sorafenib, which is an oral vascular endothelial growth factor receptor (VEGFR) inhibitor;²⁰⁷ (4) systemic chemotherapy can be administered, using dacarbazine or combinations including dacarbazine.^{85,208} (4) bisphosphonate therapy can be considered for bone metastases; and/or (5) best supportive care. In patients with metastatic medullary thyroid cancer, sorafenib reduces symptoms due to hypercalcemia and metastases.²⁰⁷ Currently, clinical trials are ongoing, studying the effectiveness of novel multi-targeted therapies including motesanib diphosphate (AMG-706),¹⁵⁹ vandetanib (in inherited disease only),²⁰⁹ sunitinib,²¹⁰ sorafenib,²¹¹ and XL 184,²¹² and pazopanib (GW786034). Of interest, calcitonin levels decreased dramatically after vandetanib therapy which did not directly correlate with changes in tumor volume, thus, calcitonin may not be a reliable marker of tumor volume in patients receiving RET inhibitor therapy.^{213,214} A study in patients with progressive metastatic MTC assessed treatment using pretargeted anti-CEA radioimmunotherapy with ¹³¹I;²¹⁵ overall survival was improved in the subset of patients with calcitonin doubling times less than 2 years.

Anaplastic Thyroid Carcinoma

Anaplastic thyroid carcinomas are aggressive undifferentiated tumors, with a disease-specific mortality approaching 100%. Patients with anaplastic carcinoma are older than those with differentiated carcinomas, with a mean age at diagnosis of approximately 65 years. Fewer than 10% of patients are younger than age 50 years, and 60% to 70% of patients are women.³⁷ Approximately 50% of patients with anaplastic carcinoma have either a prior or coexistent differentiated carcinoma. Anaplastic carcinoma develops from more differentiated tumors as a result of one or more dedifferentiating steps, particularly loss of the p53 tumor suppressor protein.²¹⁶ No precipitating events have been identified, and the mechanisms leading to anaplastic transformation of differentiated carcinomas are uncertain. Differentiated thyroid carcinomas can concentrate iodine, express TSH receptor, and produce thyroglobulin, whereas poorly differentiated or undifferentiated carcinomas typically do not. Therefore, radioiodine scanning cannot be used and radioiodine treatment is not effective in these patients.

Patients with anaplastic carcinoma present with extensive local invasion, and distant metastases are found at initial disease presentation in 15% to 50% of patients.²¹⁷ The lungs and pleura are the most common site of distant metastases, being present in up to 90% of patients with distant disease. About 5% to 15% of patients have bone metastases; 5% have brain metastases; and a few have metastases to the skin, liver, kidneys, pancreas, heart, and adrenal glands. All anaplastic carcinomas are considered stage IV (A, B, or C) (see [Table 1](#)). The T4 category includes: (1) T4a tumors which are intrathyroidal and surgically resectable; (2) T4b tumors which are extrathyroidal and not surgically resectable. However, clinically apparent anaplastic tumors are usually unresectable.

The diagnosis of anaplastic carcinoma is usually established by FNA or surgical biopsy. However, on occasion it can be difficult to discriminate

between anaplastic thyroid cancer and other primary thyroid malignancies (such as MTC, thyroid lymphoma) or poorly differentiated cancer metastatic to the thyroid.²¹⁸ Diagnostic procedures include a complete blood count, serum calcium, and TSH level. CT scans of the neck can accurately determine the extent of the thyroid tumor and can identify tumor invasion of the great vessels and upper aero-digestive tract structures.²¹⁹ CT images of the head, chest, abdomen, and pelvis are used to establish the extent of distant metastases. Bone metastases are usually lytic.

Treatment and Prognosis

No effective therapy exists for anaplastic carcinoma, and the disease is almost uniformly fatal. The median survival from diagnosis ranges from 3 to 7 months. The 1- and 5-year survival rates are about 25% and 5%, respectively.²¹⁷ Death is attributable to upper airway obstruction and suffocation (often despite tracheostomy) in 50% of these patients, and to a combination of complications of local and distant disease and/or therapy in the remaining patients. Patients with disease confined to the neck at diagnosis have a mean survival of 8 months compared with 3 months if the disease extends beyond the neck.²²⁰ Other variables that may predict a worse prognosis include older age at diagnosis, male sex, and dyspnea as a presenting symptom.

Except for patients whose tumors are small and confined entirely to the thyroid or readily excised structures, total thyroidectomy with attempted complete tumor resection has not been shown to prolong survival.^{220,221} External-beam RT, administered in conventional doses, also does not prolong survival. Treatment with single-drug chemotherapy also does not improve survival or control of disease in the neck, although perhaps 20% of patients have some response in distant metastases. The introduction of hyperfractionated RT, combined with radiosensitizing doses of doxorubicin, may increase the local response rate to about 80%, with subsequent median survival of 1 year. Distant metastases

then become the leading cause of death.²²² Similar improvement in local disease control has been reported with a combination of hyperfractionated RT and doxorubicin, followed by debulking surgery in responsive patients.²²³ However, the addition of larger doses of other chemotherapeutic drugs has not been associated with improved control of distant disease or with improved survival. Paclitaxel has been tested in newly diagnosed patients and may provide some palliative benefit.²²⁴

Once the diagnosis of anaplastic carcinoma is identified pathologically, the panel recognizes the importance of rapidly determining the potential for local resection. If the disease is deemed likely to be resectable, an attempt at total or near-total thyroidectomy should be made, with selective resection of all involved local or regional structures and nodes. The patency of the airway should be considered throughout the patient's course. Given the poor outcome with current standard therapy, all patients, regardless of surgical resection, should be considered for clinical trials. Currently, ongoing clinical trials include combretastatin A4 phosphate (CA4P) (a vascular disrupting agent), CS-7107 (an oral PPAR gamma [peroxisome proliferator-activated receptors] agonist), and novel multitargeted therapies including sorafenib and imatinib (Gleevec).^{166,225} A patient with anaplastic thyroid cancer had a durable complete response in a phase I trial with CA4P, and he has been disease free for more than 3 years.^{226,227}


Multimodality therapy should also be considered. Although optimal results have been reported with hyperfractionated RT combined with chemotherapy, the panel acknowledged that considerable toxicity is associated with such treatment and that prolonged remission is uncommonly reported. The guidelines do not recommend particular chemotherapeutic agents, either for radiosensitization or full-dose therapy, because of a lack of clear evidence of efficacy for any particular regimen.

Disclosures for the NCCN Thyroid Carcinoma Guidelines Panel

At the beginning of each panel meeting to develop NCCN guidelines, panel members disclosed financial support they have received in the form of research support, advisory committee membership, or speakers' bureau participation. Members of the panel indicated that they have received support from the following: Abbott Pharmaceuticals; American Thyroid Association; Amgen, Inc; AstraZeneca Pharmaceuticals; Bayer Pharmaceuticals Corp., Bristol-Myers Squibb; Eisai Co.; Enzon Pharmaceuticals, Inc.; Exelixis, Inc.; Genzyme Corp.; GlaxoSmithKline; ImClone; International Thyroid Study Group; Isis Pharmaceuticals, Inc.; Pfizer, Inc.; Quality Oncology, Inc.; Sanofi-Aventis and Schering-Plough Corporation. Some panel members do not accept any support from industry. The panel did not regard any potential conflicts of interest as sufficient reason to disallow participation in panel deliberations by any member.


Discussion
update in
progress

Figure 1:
Relationship of cancer recurrence and mortality to patient age at time of diagnosis



(Reprinted and adapted from AM J Med, 97, Mazzaferri EL and Jhiang SM, Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer, pp 418-428, 1994, with permission from Excerpta Medica Inc.).

Figure 2:
Relationship of cancer recurrence and mortality to tumor size



(Reprinted and adapted from AM J Med, 97, Mazzaferri EL and Jhiang SM, Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer, pp 418-428, 1994, with permission from Excerpta Medica Inc.).

Table 2**Mutations of the RET Proto-oncogene Associated with MEN 2 and Familial Medullary Thyroid Cancer (FMTC)**

Affected Codon/Exon	Clinical Syndrome(s)	Percentage of All MEN 2 Mutations
609/10	MEN 2A, FMTC	0 - 1%
611/10	MEN 2A, FMTC	2 - 3%
618/10	MEN 2A, FMTC	3 - 5%
620/10	MEN 2A, FMTC	6 - 8%
630/11	MEN 2A, FMTC	0 - 1%
634/11	MEN 2A	80-90%
635/11	MEN 2A	Rare
637/11	MEN 2A	Rare
768/13	FMTC	Rare
790/13	MEN 2A, FMTC	Rare
791/13	FMTC	Rare
804/13	MEN 2A, FMTC	0 - 1%
883/15	MEN 2B	Rare
891/15	FMTC	Rare
918/16	MEN 2B	3 - 5%
922/16	MEN 2B	Rare

With permission, from the *Annual Review of Physiology*, 2000;62:377-411 ©2000 by Annual Reviews www.AnnualReviews.org

References

1. Mazzaferri EL. Thyroid carcinoma: Papillary and follicular. In: Mazzaferri EL, Samaan N, eds. *Endocrine Tumors*. Cambridge: Blackwell Scientific Publications 1993: 278-333.
2. Ezzat S, Sarti DA, Cain DR, et al. Thyroid incidentalomas: Prevalence by palpation and ultrasonography. *Arch Intern Med* 1994;154:1838-1840.
3. Ron E, Lubin JH, Shore RE, et al. Thyroid cancer after exposure to external radiation: A pooled analysis of seven studies. *Radiat Res* 1995;141:259-277.
4. Schneider AB, Bekerman C, Leland J, et al. Thyroid nodules in the follow-up of irradiated individuals: Comparison of thyroid ultrasound with scanning and palpation. *J Clin Endocrinol Metab* 1997;82:4020-4027.
5. Ries LAG, Melbert D, Krapcho M, et al (eds). *SEER Cancer Statistics Review, 1975-2004*, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2004/ 2007. Accessed July 9, 2008.
6. Jemal A, Siegel R, Ward E, et al. *Cancer Statistics, 2008*. *CA Cancer J Clin* 2008;58:71-96.
7. Wu XC, Chen VW, Steele B, et al. Cancer incidence in adolescents and young adults in the United States, 1992-1997. *J Adolesc Health* 2003;32:405-415.
8. Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the United States, 1985-1995. *Cancer* 1998;83:2638-2648.
9. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. *Am J Med* 1994;97:418-428.
10. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. *JAMA* 2006;295:2164-2167.
11. Ito Y, Tomoda C, Uruno T, et al. Papillary microcarcinoma of the thyroid: how should it be treated? *World J Surg* 2004;28(11):1115-1121.
12. Sherman SI. Thyroid carcinoma. *The Lancet* 2003;361:501-511.
13. Wong FL, Ron E, Gierlowski T, et al. Benign thyroid tumors: General risk factors and their effects on radiation risk estimation. *Am J Epidemiol* 1996;144:728-733.
14. Hall P, Holm LE. Radiation-associated thyroid cancer—facts and fiction. *Acta Oncol* 1998;37:325-330.
15. Ron E, Doddy MM, Becker DV, et al. Cancer mortality following treatment for adult hyperthyroidism. *JAMA* 1998;280:347-355.
16. Jacob P, Goulko G, Heidenreich WF, et al. Thyroid cancer risk to children calculated. *Nature* 1998;392:31-32.
17. Schneider AB. Radiation-induced thyroid tumors. *Endocrinol Metab Clin North Am* 1990;19:495-508.
18. Nikiforov YE, Nikiforova M, Fagin JA. Radiation-induced post-Chernobyl pediatric thyroid carcinomas. *Oncogene* 1998;17:1983-1988.
19. Tan GH, Gharib H. Thyroid incidentalomas: Management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. *Ann Intern Med* 1997;126:226-231.
20. Cooper DS, Doherty GM, Haugen BR, et al; The American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. *Thyroid* 2006;16:109-142.
21. Frates MC, Benson CB, Charboneau JW, et al. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound Consensus Conference Statement. *Radiology* 2005;237:794-800.
22. Mazzaferri EL. Thyroid cancer in thyroid nodules: Finding a needle in the haystack (editorial). *Am J Med* 1992;93:359-362.

23. Hamming JF, Goslings BM, van Steenis GJ, et al. The value of fine-needle aspiration biopsy in patients with nodular thyroid disease divided into groups of suspicion of malignant neoplasms on clinical grounds. *Arch Intern Med* 1990;150:113-116.
24. Belfiore A, La Rosa GL, LaPorta GA, et al. Cancer risk in patients with cold thyroid nodules: Relevance of iodine intake, sex, age, and multinodularity. *Am J Med* 1992;93:363-369.
25. Chan BK, Desser TS, McDougall IR, et al. Common and uncommon sonographic features of papillary thyroid carcinoma. *J Ultrasound Med* 2003;22:1083-1090.
26. Henry JF, Denizot A, Puccini M, et al. Early diagnosis of sporadic medullary cancer of the thyroid: Contribution of routine calcitonin assay. *Presse Med* 1996;25:1583-1588.
27. Singer PA, Cooper DS, Daniels GH, et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. *Arch Intern Med* 1996;156:2165-2172.
28. Cheung K, Roman SA, Wang TS, et al. Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis. *J Clin Endocrinol Metab* 2008;93(6):2173-2180. Epub 2008 Mar 25.
29. Koike E, Noguchi S, Yamashita H, et al. Ultrasonographic characteristics of thyroid nodules: prediction of malignancy. *Arch Surg* 2001;136(3):334-337.
30. Yeh MW, Demircan O, Ituarte P, et al. False-negative fine-needle aspiration cytology results delay treatment and adversely affect outcome in patients with thyroid carcinoma. *Thyroid* 2004;14(3):207-215.
31. Cersosimo E, Gharib H, Suman VJ, et al. "Suspicious" thyroid cytologic findings: Outcome in patients without immediate surgical treatment. *Mayo Clin Proc* 1993;68:343-348.
32. Richter B, Neises G, Clar C. Pharmacotherapy for thyroid nodules. A systematic review and meta-analysis. *Endocrinol Metab Clin North Am* 2002;31:699-722.
33. Castro MR, Caraballo PJ, Morris JC. Effectiveness of thyroid hormone suppressive therapy in benign solitary thyroid nodules: a meta-analysis. *J Clin Endocrinol Metab* 2002;87:4154-4159.
34. McHenry CR, Walfish PG, Rosen IB. Non-diagnostic fine needle aspiration biopsy: a dilemma in management of nodular thyroid disease. *Am Surg* 1993;59:415-419.
35. Newman KD, Black T, Heller G, et al. Differentiated thyroid cancer: Determinants of disease progression in patients < 21 years of age at diagnosis—a report from the Surgical Discipline Committee of the Children's Cancer Group. *Ann Surg* 1998;227:533-541.
36. Robie DK, Dinauer CW, Tuttle RM, et al. The impact of initial surgical management on outcome in young patients with differentiated thyroid cancer. *J Pediatr Surg* 1998;33:1134-1138.
37. Gilliland FD, Hunt WC, Morris DM, et al. Prognostic factors for thyroid carcinoma: A population-based study of 15,698 cases from the surveillance, epidemiology, and end results (SEER) program, 1973-1991. *Cancer* 1997;79:564-573.
38. Sherman SI, Brierley JD, Sperling M, et al. Prospective multicenter study of treatment of thyroid carcinoma: Initial analysis of staging and outcome. *Cancer* 1998;83:1012-1021.
39. Tsang RW, Brierley JD, Simpson WJ, et al. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. *Cancer* 1998;82:375-388.
40. Mazzaferri EL. Management of a solitary thyroid nodule. *N Engl J Med* 1993;328:553-559.
41. Dottorini ME, Vignati A, Mazzucchelli L, et al. Differentiated thyroid carcinoma in children and adolescents: A 37-year experience in 85 patients. *J Nucl Med* 1997;38:669-675.

42. Samuel AM, Rajashekharrao B, Shah DH. Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer. *J Nucl Med* 1998;39:1531-1536.
43. Schlumberger M, De Vathaire F, Travagli JP, et al. Differentiated thyroid carcinoma in childhood: Long-term follow-up of 72 patients. *J Clin Endocrinol Metab* 1987;65:1088-1094.
44. Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: Development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. *Surgery* 1993;114:1050-1058.
45. Shaha AR, Loree TR, Shah JP. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. *Surgery* 1995;118:1131-1138.
46. Cady B. Staging in thyroid carcinoma. *Cancer* 1998;83:844-847.
47. DeGroot LJ, Kaplan EL, Straus FH, et al. Does the method of management of papillary thyroid carcinoma make a difference in outcome? *World J Surg* 1994;18:123-130.
48. Miccoli P, Antonelli A, Spinelli C, et al. Completion total thyroidectomy in children with thyroid cancer secondary to the Chernobyl accident. *Arch Surg* 1998;133:89-93.
49. Palme CE, Waseem Z, Raza SN, et al. Management and outcome of recurrent well-differentiated thyroid carcinoma. *Arch Otolaryngol Head Neck Surg* 2004;130(7):819-824.
50. Frankenthaler RA, Sellin RV, Cangir A, et al. Lymph node metastasis from papillary-follicular thyroid carcinoma in young patients. *Am J Surg* 1990;160:341-343.
51. Agostini L, Mazzi P, Cavaliere A. Multiple primary malignant tumours: Gemistocytic astrocytoma with leptomeningeal spreading and papillary thyroid carcinoma: A case report. *Acta Neurol (Napoli)* 1990;12:305-310.
52. Soravia C, Sugg SL, Berk T, et al. Familial adenomatous polyposis-associated thyroid cancer: A clinical, pathological, and molecular genetics study. *Am J Pathol* 1999;154:127-135.
53. Stratakis CA, Courcoutsakis NA, Abati A, et al. Thyroid gland abnormalities in patients with the syndrome of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas (Carney complex). *J Clin Endocrinol Metab* 1997;82:2037-2043.
54. Marsh DJ, Dahia PLM, Caron S, et al. Germline PTEN mutations in Cowden syndrome-like families. *J Med Genet* 1998;35:881-885.
55. Mazzaferri EL. Papillary thyroid carcinoma: Factors influencing prognosis and current therapy. *Semin Oncol* 1987;14:315-332.
56. LiVolsi VA. Follicular lesions of the thyroid. In: LiVolsi VA, ed. *Surgical Pathology of the Thyroid*. Philadelphia: WB Saunders 1990:173-212.
57. LiVolsi VA. Papillary lesions of the thyroid. In LiVolsi VA, ed. *Surgical Pathology of the Thyroid*. Philadelphia: WB Saunders 1990:136-172.
58. Elisei R, Cosci B, Romei C, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. *J Clin Endocrinol Metab* 2008;93(3):682-687. Epub 2007 Dec 11.
59. LiVolsi VA. Unusual variants of papillary thyroid carcinoma. In: Mazzaferri EL, Kreisberg RA, Bar RS, eds. *Advances in Endocrinology and Metabolism*. St. Louis: Mosby-Year Book 1995:39-54.
60. Tielens ET, Sherman SI, Hruban RH, et al. Follicular variant of papillary thyroid carcinoma: A clinicopathologic study. *Cancer* 1994;73:424-431.
61. van Heerden JA, Hay ID, Goellner JR, et al. Follicular thyroid carcinoma with capsular invasion alone: A nonthreatening malignancy. *Surgery* 1992;112:1130-1138.

62. LiVolsi V, Asa SL. The demise of follicular carcinoma of the thyroid gland. *Thyroid* 1994;4:233-236.
63. Brennan MD, Bergstralh EJ, van Heerden JA, et al. Follicular thyroid cancer treated at the Mayo Clinic, 1946 through 1970: Initial manifestations, pathologic findings, therapy, and outcome. *Mayo Clin Proc* 1991;66:11-22.
64. Greene FL, Page DL, Fleming ID, et al, eds. *AJCC Cancer Staging Manual*, 6th ed. New York: Springer-Verlag, 2002:77-87.
65. Fleming ID, Cooper JS, Henson DE, et al, eds. *AJCC Cancer Staging Manual*, 5th ed. Philadelphia: Lippincott Williams & Wilkins, 1997:59.
66. Hedinger CE. Problems of classification of thyroid tumors and their bearing on prognosis and therapy. *Schweiz Med Wochenschr* 1993;123:1673-1681.
67. Belchetz G, Cheung CC, Freeman J, et al. Hürthle cell tumors: using molecular techniques to define a novel classification system. *Arch Otolaryngol Head Neck Surg* 2002;128:237-240.
68. Chen H, Nicol TL, Zeiger MA, et al. Hürthle cell neoplasms of the thyroid: Are there factors predictive of malignancy? *Ann Surg* 1998;227:542-546.
69. Thompson NW, Dunn EL, Batsakis JG, et al. Hürthle cell lesions of the thyroid gland. *Surg Gynecol Obstet* 1973;139:555-560.
70. Lopez-Penabad L, Chiu AC, Hoff AO, et al. Prognostic factors in patients with Hürthle cell neoplasms of the thyroid. *Cancer* 2003;97:1186-1194.
71. Khafif A, Khafif RA, Attie JN. Hürthle cell carcinoma: A malignancy of low-grade potential. *Head Neck* 1999;21:506-511.
72. Ruegemer JJ, Hay ID, Bergstralh EJ, et al. Distant metastases in differentiated thyroid carcinoma: A multivariate analysis of prognostic variables. *J Clin Endocrinol Metab* 1988;67:501-558.
73. Samaan NA, Schultz PN, Hickey RC, et al. Well-differentiated thyroid carcinoma and the results of various modalities of treatment: A retrospective review of 1599 patients. *J Clin Endocrinol Metab* 1992;75:714-720.
74. Samaan NA, Schultz PN, Haynie TP, et al. Pulmonary metastasis of differentiated thyroid carcinoma: Treatment results in 101 patients. *J Clin Endocrinol Metab* 1985;60:376-380.
75. Moosa M, Mazzaferri EL. Occult thyroid carcinoma. *Cancer J* 1997;10:180-188.
76. Baudin E, Travagli JP, Ropers J, et al. Microcarcinoma of the thyroid gland: The Gustave-Roussy Institute experience. *Cancer* 1998;83:553-559.
77. Sugino K, Ito K Jr, Ozaki O, et al. Papillary microcarcinoma of the thyroid. *J Endocrinol Invest* 1998;21:445-448.
78. Hay ID. Papillary thyroid carcinoma. *Endocrinol Metab Clin North Am* 1990;19:545-576.
79. Emerick GT, Duh Q-Y, Siperstein AE, et al. Diagnosis, treatment, and outcome of follicular thyroid carcinoma. *Cancer* 1993;72:3287-3295.
80. Salvesen H, Njolstad PR, Akslen LA, et al. Papillary thyroid carcinoma: A multivariate analysis of prognostic factors including an evaluation of the p-TNM staging system. *Eur J Surg* 1992;158:583-589.
81. Pingpank JF Jr, Sasson AR, Hanlon AL, et al. Tumor above the spinal accessory nerve in papillary thyroid cancer that involves lateral neck nodes: a common occurrence. *Arch Otolaryngol Head Neck Surg* 2002;128:1275-1278.
82. Yamashita H, Noguchi S, Murakami N, et al. Extracapsular invasion of lymph node metastasis is an indicator of distant metastasis and poor prognosis in patients with thyroid papillary carcinoma. *Cancer* 1997;80:2268-2272.

83. Sellers M, Beenken S, Blankenship A, et al. Prognostic significance of cervical lymph node metastases in differentiated thyroid cancer. *Am J Surg* 1992;164:578-581.
84. Lindegaard MW, Paus E, Hie J, et al. Thyroglobulin radioimmunoassay and ¹³¹I scintigraphy in patients with differentiated thyroid carcinoma. *Acta Chir Scand* 1988;154:141-145.
85. Schlumberger M, Challeton C, De Vathaire F, et al. Treatment of distant metastases of differentiated thyroid carcinoma. *J Endocrinol Invest* 1995;18:170-172.
86. Sisson JC, Giordano TJ, Jamadar DA, et al. ¹³¹I treatment of micronodular pulmonary metastases from papillary thyroid carcinoma. *Cancer* 1996;78:2184-2192.
87. Brown AP, Greening WP, McCready VR, et al. Radioiodine treatment of metastatic thyroid carcinoma: The Royal Marsden Hospital experience. *Br J Radiol* 1984;57:323-327.
88. Casara D, Rubello D, Saladini G, et al. Different features of pulmonary metastases in differentiated thyroid cancer: Natural history and multivariate statistical analysis of prognostic variables. *J Nucl Med* 1993;34:1626-1631.
89. Cady B. Our AMES is true: How an old concept still hits the mark, or risk group assignment points the arrow to rational therapy selection in differentiated thyroid cancer. *Am J Surg* 1997;174:462-468.
90. Cady B, Sedgwick CE, Meissner WA, et al. Risk factor analysis in differentiated thyroid cancer. *Cancer* 1979;43:810-820.
91. Loh KC, Greenspan FS, Gee L, et al. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: A retrospective analysis of 700 patients. *J Clin Endocrinol Metab* 1997;82:3553-3562.
92. Lin JD, Kao PF, Weng HF, et al. Relative value of thallium-201 and iodine-131 scans in the detection of recurrence or distant metastasis of well differentiated thyroid carcinoma. *Eur J Nucl Med* 1998;25:695-700.
93. Brierley JD, Panzarella T, Tsang RW, et al. A comparison of different staging systems predictability of patient outcome: Thyroid carcinoma as an example. *Cancer* 1997;79:2414-2423.
94. Sherman SI. Toward a standard clinicopathologic staging approach for differentiated thyroid carcinoma. *Semin Surg Oncol* 1999;16:12-15.
95. Van De Velde CJH, Hamming JF, Goslings BM, et al. Report of the consensus development conference on the management of differentiated thyroid cancer in the Netherlands. *Eur J Cancer Clin Oncol* 1988;24:287-292.
96. Solomon BL, Wartofsky L, Burman KD. Current trends in the management of well-differentiated papillary thyroid carcinoma. *J Clin Endocrinol Metab* 1996;81:333-339.
97. Hay ID, Grant CS, Taylor WF, et al. Ipsilateral lobectomy vs bilateral lobar resection in papillary thyroid carcinoma: A retrospective analysis of surgical outcome using a novel prognostic scoring system. *Surgery* 1987;102:1088-1095.
98. Hay ID, Grant CS, Bergstralh EJ, et al. Unilateral total lobectomy: Is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? *Surgery* 1998;124:958-966.
99. Dackiw AP, Zeiger M. Extent of surgery for differentiated thyroid cancer. *Surg Clin North Am* 2004;84(3):817-832.
100. Mazzaferri EL. Treating differentiated thyroid carcinoma: Where do we draw the line? *Mayo Clin Proc* 1991;66:105-111.
101. Massin JP, Savoie JC, Garnier H, et al. Pulmonary metastases in differentiated thyroid carcinoma: Study of 58 cases with implications for the primary tumor treatment. *Cancer* 1984;53:982-992.
102. Shaha AR. Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer. *Laryngoscope* 2004;114:393-402.

103. DeGroot LJ, Kaplan EL. Second operations for "completion" of thyroidectomy in treatment of differentiated thyroid cancer. *Surgery* 1991;110:936-940.
104. Mettlin C, Lee F, Drago J, et al. The American Cancer Society National Prostate Cancer Detection Project. *Cancer* 1991;67:2949-2958.
105. Pasiaka JL, Thompson NW, McLeod MK, et al. The incidence of bilateral well-differentiated thyroid cancer found at completion thyroidectomy. *World J Surg* 1992;16:711-716.
106. Scheumann GFW, Seeliger H, Musholt TJ, et al. Completion thyroidectomy in 131 patients with differentiated thyroid carcinoma. *Eur J Surg* 1996;162:677-684.
107. Chao TC, Jeng LB, Lin JD, et al. Completion thyroidectomy for differentiated thyroid carcinoma. *Otolaryngol Head Neck Surg* 1998;118:896-899.
108. Burge MR, Zeise TM, Johnsen MW, et al. Risks of complication following thyroidectomy. *J Gen Intern Med* 1998;13:24-31.
109. Dralle H, Gimm O, Simon D, et al. Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. *World J Surg* 1998;22:744-751.
110. Udelsman R, Lakatos E, Ladenson P. Optimal surgery for papillary thyroid carcinoma. *World J Surg* 1996;20:88-93.
111. Pattou F, Combemale F, Fabre S, et al. Hypocalcemia following thyroid surgery: Incidence and prediction of outcome. *World J Surg* 1998;22:718-724.
112. Sosa JA, Bowman HM, Tielsch JM, et al. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. *Ann Surg* 1998;228:320-328.
113. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. *J Clin Endocrinol Metab* 2001;86(4):1447-1463.
114. Mazzaferri EL. Thyroid remnant 131-I ablation for papillary and follicular thyroid carcinoma. *Thyroid* 1997;7:265-271.
115. Taylor T, Specker B, Robbins J, et al. Outcome after treatment of high-risk papillary and non-Hürthle-cell follicular thyroid carcinoma. *Ann Intern Med* 1998;129:622-627.
116. Leger FA, Izembart M, Dagousset F, et al. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. *Eur J Nucl Med* 1998;25:242-246.
117. Muratet JP, Giraud P, Daver A, et al. Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma. *J Nucl Med* 1997;38:1362-1368.
118. Mazzaferri EL. Carcinoma of follicular epithelium: Radioiodine and other treatment outcomes. In: Braverman LE, Utiger RD, eds. *The Thyroid: A Fundamental and Clinical Text*. Philadelphia: Lippincott-Raven, 1996:922-945.
119. Brierley J, Maxon HR. Radioiodine and external radiation therapy in the treatment of thyroid cancer. In: Fagin JA, ed. *Thyroid Cancer*. Boston/Dordrecht/London: Kluwer Academic 1998:285-317.
120. Tuttle RM, Leboeuf R, Robbins RJ, et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. *J Nucl Med* 2006;47(10):1587-1591. Erratum in: *J Nucl Med* 2007;48(1):7.
121. Van Nostrand D, Wartofsky L. Radioiodine in the treatment of thyroid cancer. *Endocrinol Metab Clin North Am* 2007;36(3):807-822, vii-viii.
122. Maxon HR, Englaro EE, Thomas SR, et al. Radioiodine-131 therapy for well-differentiated thyroid cancer—a quantitative radiation

dosimetric approach: Outcome and validation in 85 patients. *J Nucl Med* 1992;33:1132-1136.

123. Benua RS, Cicale NR, Sonenberg M, et al. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. *Am J Roentgenol* 1962;87:171-178.

124. Sherman SI, Tielens ET, Sostre S, et al. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. *J Clin Endocrinol Metab* 1994;78:629-634.

125. Pacini F, Molinaro E, Castagna MG, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. *J Clin Endocrinol Metab* 2003;88(8):3668-3673.

126. Pacini F, Lari R, Mazzeo S, et al. Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer. *Clin Endocrinol* 1985;23:405-411.

127. Haugen B, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. *J Clin Endocrinol Metab* 1999;84:3877-3885.

128. Kloos RT, Mazzaferri EL. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. *J Clin Endocrinol Metab* 2005;90(9):5047-5057. Epub 2005 Jun 21.

129. Ladenson PW, Braverman LE, Mazzaferri EL, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. *N Engl J Med* 1997;337:888-896.

130. Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH (rhTSH) useful in the follow-up of differentiated thyroid cancer after thyroid ablation? *J Clin Endocrinol Metab* 2002;87(4):1490-1498.

131. Kloos RT, Mazzaferri EL. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. *J Clin Endocrinol Metab* 2005;90(9):5047-5057. Epub 2005 Jun 21.

132. Castagna MG, Brilli L, Pilli T, et al. Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. *J Clin Endocrinol Metab* 2008;93(1):76-81. Epub 2007 Oct 30.

133. Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyroglobulin assays. *Clin Chem* 1996;42:164-173.

134. Spencer CA, Lopresti JS. Measuring thyroglobulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer. *Nat Clin Pract Endocrinol Metab* 2008;4(4):223-233. Epub 2008 Feb 12.

135. Spencer CA, Takeuchi M, Kazarosyan M, et al. Serum thyroglobulin autoantibodies: Prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. *J Clin Endocrinol Metab* 1998;83:1121-1127.

136. Chung JK, Park YJ, Kim TY, et al. Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. *Clin Endocrinol* 2002;57:215-221.

137. Chiovato L, Latrofa F, Braverman LE, et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. *Ann Intern Med* 2003;139:346-351.

138. Ringel M, Ladenson P, Levine MA. Molecular diagnosis of residual and recurrent thyroid cancer by amplification of thyroglobulin messenger ribonucleic acid in peripheral blood. *J Clin Endocrinol Metab* 1998;83:4435-4442.

139. Ringel MD. Molecular detection of thyroid cancer: differentiating "signal" and "noise" in clinical assays. *J Clin Endocrinol Metab* 2004;89:29-32.
140. Schlumberger M, Mancusi F, Baudin E, et al. 131-I therapy for elevated thyroglobulin levels. *Thyroid* 1997;7:273-276.
141. Schlumberger M, Tubiana M, De Vathaire F, et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. *J Clin Endocrinol Metab* 1986;63:960-967.
142. Pacini F, Lippi F, Formica N, et al. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. *J Nucl Med* 1987;28:1888-1891.
143. Pineda JD, Lee T, Ain K, et al. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. *J Clin Endocrinol Metab* 1995;80:1488-1492.
144. Mazzaferri EL. Treating high thyroglobulins with radioiodine: A magic bullet or a shot in the dark? *J Clin Endocrinol Metab* 1995;80:1485-1487.
145. Pacini F, Agate L, Elisei R, et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic 131-I whole body scan: comparison of patients treated with high 131-I activities versus untreated patients. *J Clin Endocrinol Metab* 2001;86:4092-4097.
146. Burns JA, Morgenstern KE, Cahill KV, et al. Nasolacrimal obstruction secondary to I(131) therapy. *Ophthal Plast Reconstr Surg* 2004;20(2):126-129.
147. McGriff NJ, Csako G, Gourgiotis L, et al. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. *Ann Med* 2002;34(7-8):554-564.
148. Pujol P, Daures JP, Nsakala N, et al. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. *J Clin Endocrinol Metab* 1996;81:4318-4323.
149. Cooper DS, Specker B, Ho M, et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: Results from the National Thyroid Cancer Treatment Cooperative Registry. *Thyroid* 1998;8:737-744.
150. Burmeister LA, Goumaz MO, Mariash CN, et al. Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer. *J Clin Endocrinol Metab* 1992;75:344-350.
151. Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. *Thyroid* 2006;16(12):1229-1242.
152. Biermann M, Pixberg MK, Schuck A, et al. Multicenter study differentiated thyroid carcinoma (MSDS). Diminished acceptance of adjuvant external beam radiotherapy. *Nuklearmedizin* 2003;42:244-250.
153. Farahati J, Reiners C, Stuschke M, et al. Differentiated thyroid cancer: Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4). *Cancer* 1996;77:172-180.
154. Simpson WJ, Panzarella T, Carruthers JS, et al. Papillary and follicular thyroid cancer: Impact of treatment in 1578 patients. *Int J Radiat Oncol Biol Phys* 1988;14:1063-1075.
155. Chiu AC, Delpassand ES, Sherman SI. Prognosis and treatment of brain metastases in thyroid carcinoma. *J Clin Endocrinol Metab* 1997;82:3637-3642.
156. Droz JP, Schlumberger M, Rougier P, et al. Chemotherapy in metastatic nonanaplastic thyroid cancer: Experience at the Institut Gustave-Roussy. *Tumori* 1990;76:480-483.
157. Ahuja S, Ernst H. Chemotherapy of thyroid carcinoma. *J Endocrinol Invest* 1987;10:303-310.
158. Mrozek E, Kloos RT, Ringel MD, et al. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. *J Clin Endocrinol Metab* 2006;91(6):2201-2204. Epub 2006 Mar 7.

159. Rosen LS, Kurzrock R, Mulay M, et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. *J Clin Oncol* 2007;25:2369-2376.
160. Sherman SI, Wirth LJ, Droz JP, et al; Motesanib Thyroid Cancer Study Group. Motesanib diphosphate in progressive differentiated thyroid cancer. *N Engl J Med* 2008;359(1):31-42.
161. Kloos R, Ringel M, Knopp M, et al. Significant clinical and biologic activity of RAF/VEGF-R kinase inhibitor BAY 43-9006 in patients with metastatic papillary thyroid carcinoma (PTC): Updated results of a phase II study. *J Clin Oncol (ASCO Annual Meeting Proceedings)* 2006:5534.
162. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. *J Clin Oncol* 2008 Jun 9. [Epub ahead of print]
163. Cohen EE, Leedles BM, Cullen KJ, et al. Phase 2 study of sunitinib in refractory thyroid cancer [abstract]. *J Clin Oncol* 2008;26:6025.
164. Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. *J Clin Oncol* 2008 Jun 9. [Epub ahead of print]
165. Ain KB, Lee C, Holbrook KM, et al. Phase II study of lenalidomide in distantly metastatic, rapidly progressive, and radioiodine-unresponsive thyroid carcinomas: preliminary results [abstract]. *J Clin Oncol* 2008;26:6027.
166. Deshpande HA, Gettinger SN, Sosa JA. Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope. *Curr Opin Oncol* 2008;20(1):19-24.
167. Kouvaraki MA, Shapiro SE, Fornage BD, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. *Surgery* 2003;134:946-954; discussion 954-955.
168. Haigh PI, Urbach DR, Rotstein LE. Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer. *Ann Surg Oncol* 2005;12:81-89. Epub 2004 Dec 27.
152. Morris LF, Waxman AD, Braunstein GD. Thyroid stunning. *Thyroid* 2003;13:333-340.
169. Morris LF, Waxman AD, Braunstein GD. Thyroid stunning. *Thyroid* 2003;13:333-340.
170. Eustatia-Rutten CF, Romijn JA, Guijt MJ, et al. Outcome of palliative embolization of bone metastases in differentiated thyroid carcinoma. *J Clin Endocrinol Metab* 2003;88:3184-3189.
171. Van Nostrand D, Atkins F, Yeganeh F, et al. Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. *Thyroid* 2002;12:121-134.
172. Thompson LD, Wieneke JA, Paal E, et al. A clinicopathologic study of minimal invasive follicular carcinoma of the thyroid gland with a review of the English literature. *Cancer* 2001;91:505-524.
173. Sugino K, Ito K, Mimura T, et al. Hürthle cell tumor of the thyroid: analysis of 188 cases. *World J Surg* 2001;25(9):1160-1163.
174. Lopez-Penabad L, Chiu AC, Hoff AO, et al. Prognostic factors in patients with Hürthle cell neoplasms of the thyroid. *Cancer* 2003;97(5):1186-1194.
175. Herrera MF, Hay ID, Wu PS, et al. Hurthle cell (oxyphilic) papillary thyroid carcinoma: a variant with more aggressive biologic behavior. *World J Surg* 1992;16:669-674.
176. Ball DW, Baylin SB, de Bustros AC. Medullary thyroid carcinoma. In: Braverman LE, Utiger RD, eds. *Werner and Ingbar's The Thyroid*, 7th ed. Philadelphia: Lippincott-Raven 1996:946-960.
177. Gertner ME, Kebebew E. Multiple endocrine neoplasia type 2. *Curr Treat Options Oncol* 2004;5(4):315-325.

178. Raue F, Frank-Raue K. Multiple endocrine neoplasia type 2: 2007 update. *Horm Res* 2007;68 Suppl 5:101-104. Epub 2007 Dec 10.
179. Saad MF, Ordonez NG, Rashid RK, et al. Medullary carcinoma of the thyroid. *Medicine* 1984;63:319-342.
180. Pacini F, Fontanelli M, Fugazzola L, et al. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. *J Clin Endocrinol Metab* 1994;78:826-829.
181. Niccoli P, Wion-Barbot N, Caron P, et al. Interest of routine measurement of serum calcitonin: Study in a large series of thyroidectomized patients. *J Clin Endocrinol Metab* 1997;82:338-341.
182. Ozgen AG, Hamulu F, Bayraktar F, et al. Evaluation of routine basal serum calcitonin measurement for early diagnosis of medullary thyroid carcinoma in seven hundred seventy-three patients with nodular goiter. *Thyroid* 1999;9:579-582.
183. Horvit PK, Gagel RF. The goitrous patient with an elevated serum calcitonin: What to do? *J Clin Endocrinol Metab* 1997;82:335-337.
184. Hodak SP, Burman KD. The calcitonin conundrum—is it time for routine measurement of serum calcitonin in patients with thyroid nodules [Editorial]? *J Clin Endocrinol Metab* 2004;89:511-514.
185. Gagel RF, Cote GJ. Pathogenesis of medullary thyroid carcinoma. In: Fagin JA, ed. *Thyroid Cancer Boston/Dordrecht/London*: Kluwer Academic 1998:85-103.
186. Papi G, Corsello SM, Cioni K, et al. Value of routine measurement of serum calcitonin concentrations in patients with nodular thyroid disease: A multicenter study. *J Endocrinol Invest* 2006;29(5):427-437.
187. Kouvaraki MA, Shapiro SE, Perrier ND, et al. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. *Thyroid* 2005;15(6):531-544.
188. Wohllk N, Cote GJ, Bugalho MMJ, et al. Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. *J Clin Endocrinol Metab* 1996;81:3740-3745.
189. Dottorini ME, Assi A, Sironi M, et al. Multivariate analysis of patients with medullary thyroid carcinoma: Prognostic significance and impact on treatment of clinical and pathologic variables. *Cancer* 1996;77:1556-1565.
190. DeGroot LJ. Thyroid carcinoma. *Med Clin North Am* 1975;59:1233-1246.
191. Samaan NA, Schultz PN, Hickey RC. Medullary thyroid carcinoma: Prognosis of familial versus sporadic disease and the role of radiotherapy. *J Clin Endocrinol Metab* 1988;67:801-805.
192. O'Riordain DS, O'Brien T, Weaver AL, et al. Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. *Surgery* 1994;116:1017-1023.
193. Lippman SM, Mendelsohn G, Trump DL, et al. The prognostic and biological significance of cellular heterogeneity in medullary thyroid carcinoma: a study of calcitonin, L-dopa decarboxylase, and histaminase. *J Clin Endocrinol Metab* 1982;54:233-240.
194. Mendelsohn G, Wells SA, Baylin SB. Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. *Cancer* 1984;54:657-662.
195. Maldonado MR, Sherman SI. Predictive value of clinicopathologic staging for medullary thyroid carcinoma. 72nd Annual Meeting of the American Thyroid Association. 1999; Palm Beach, FL.
196. Romei C, Elisei R, Pinchera A, et al. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. *J Clin Endocrinol Metab* 1996;81:1619-1622.
197. Ogilvie JB, Kebebew E. Indication and timing of thyroid surgery for patients with hereditary medullary thyroid cancer syndromes. *J Natl Compr Canc Netw* 2006;4:139-147.

198. Learoyd DL, Gosnell J, Elston MS, et al. Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations. *Clin Endocrinol (Oxf)*. 2005 Dec;63(6):636-41.
199. Brandi ML, Gagel RF, Angeli A, et al. Consensus: Guidelines for diagnosis and therapy of MEN type 1 and type 2. *J Clin Endocrinol Metab* 2001;86:5658-5671.
200. Machens A, Niccoli-Sire P, Hoegel J, et al. Early malignant progression of hereditary medullary thyroid cancer. *N Engl J Med* 2003;349(16):1517-1525.
201. Skinner MA, Moley JA, Dilley WG, et al. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. *N Engl J Med* 2005;353:1105-1113.
202. van Heerden JA, Grant CS, Gharib H, et al. Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. *Ann Surg* 1990;212:395-401.
203. Scopsi L, Sampietro G, Boracchi P, et al. Multivariate analysis of prognostic factors in sporadic medullary carcinoma of the thyroid. *Cancer* 1996;78:2173-2183.
204. Tisell LE, Hansson G, Jansson S, et al. Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. *Surgery* 1986;99:60-66.
205. Moley JF, Debenedetti MK, Dilley WG, et al. Surgical management of patients with persistent or recurrent medullary thyroid cancer. *J Intern Med* 1998;243:521-526.
206. Fleming JB, Lee JE, Bouvet M, et al. Surgical strategy for the treatment of medullary thyroid carcinoma. *Ann Surg* 1999;230:697-707.
207. Kober F, Hermann M, Handler A, et al. Effect of sorafenib in symptomatic metastatic medullary thyroid cancer [abstract]. *J Clin Oncol* 2007;25:14065.
208. Nocera M, Baudin E, Pellegriti G, et al. Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU dacarbazine. Groupe d'Etude des Tumeurs a Calcitonine (GETC). *Br J Cancer* 2000;83:715-718.
209. Haddad RI, Krebs AD, Vasselli J, et al. A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer [abstract]. *J Clin Oncol* 2008;26:6024.
210. Goulart B, Carr L, Martins RG, et al. Phase II study of sunitinib in iodine refractory, well-differentiated thyroid cancer (WDTC) and metastatic medullary thyroid carcinoma (MTC) [abstract]. *J Clin Oncol* 2008;26:6062.
211. Hong D, Ye L, Gagel R, et al. Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. *Mol Cancer Ther* 2008 Apr 29 [Epub ahead of print]
212. Salgia R, Sherman S, Hong DS, et al. A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC) [abstract]. *J Clin Oncol* 26: 2008;26:3522.
213. Wells SYY, Lakhani V, Hou J. A phase II trial of ZD6474 in patients with hereditary metastatic medullary thyroid cancer [abstract]. *J Clin Oncol* 2006;24:5553.
214. Wells SA, Gosnell JE, Gagel RF, et al. Vandetanib in metastatic hereditary medullary thyroid cancer: Follow-up results of an open-label phase II trial [abstract]. *J Clin Oncol* 2007;25(18S):6018.
215. Chatal JF, Campion L, Kraeber-Bodere F, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. *J Clin Oncol* 2006;24:1705-1711. Epub 2006 Mar 20.
216. Moretti F, Farsetti A, Soddu S, et al. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. *Oncogene* 1997;14:729-740.

217. Sherman SI. Anaplastic carcinoma: Clinical aspects. In: Wartofsky L, ed. Thyroid Cancer: A Comprehensive Guide to Clinical Management. Totowa, NJ: Humana Press 1999:319-325. anaplastic thyroid carcinoma [abstract]. J Clin Oncol 2006;24(18S):5580.
218. Asa SL, Bedard YC. Fine-needle aspiration cytology and histopathology. In: Clark OH, Noguchi S, eds. Thyroid Cancer: Diagnosis and Treatment. St Louis. Quality Medical Publishing, 2000:105-126.
219. Takashima S, Morimoto S, Ikezoe J, et al. CT evaluation of anaplastic thyroid carcinoma. Am J Roentgenol 1990;154:1079-1085.
220. Venkatesh YSS, Ordonez NG, Schultz PN, et al. Anaplastic carcinoma of the thyroid: a clinicopathologic study of 121 cases. Cancer 1990;66:321-330.
221. Junor EJ, Paul J, Reed NS. Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol 1992;18:83-88.
222. Kim JH, Leeper RD. Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 1987;60:2372-2375.
223. Wallin G, Lundell G, Tennvall J. Anaplastic giant cell thyroid carcinoma. Scand J Surg 2004;93(4):272-277.
224. Ain KB. Anaplastic thyroid carcinoma. Behavior, biology, and therapeutic approaches. Thyroid 1998;8:715-726.
225. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10(2):415-427.
226. Dowlati A, Robertson K, Cooney M, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002;62:3408-3416.
227. Cooney MM, Savvides P, Agarwala SS, et al. Phase II study of combretastatin A4 phosphate (CA4P) in patients with advanced

Discussion
update in
progress